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ABSTRACT 
Klebsiella pneumoniae is a Gram-negative bacillus from the Enterobacteriaceae family 
responsible for a significant number of community-acquired infections worldwide. K. 
pneumoniae strains are frequently multidrug resistant (MDR), that is, resistant to three or more classes 
of antibiotics. The increasing emergence of K. pneumoniae strains producing extended-spectrum β-
lactamases (ESBLs) and plasmid-encoded carbapenemases has become a major cause of concern 
worldwide due to the lack of alternative therapeutic options and the high morbidity and mortality rates 
associated with infections by these strains in hospital settings. Antibiotic resistance is often acquired by 
the horizontal transfer of resistance genes on mobile elements like plasmids. Plasmids are a key vehicle 
for bacterial evolution and they promote the lateral gene transfer between different genera of bacteria 
via conjugation and transformation. Their replication is regulated by the basic replicon. In the past it 
was believed that it was not possible for plasmids with the same replicon type to coexist in the same 
cell. Based on this concept of incompatibility, plasmids were sorted into different Inc groups. 
Additionally, antimicrobial resistance genes can be mobilized through the acquisition of mobile 
elements in plasmids, such as transposable elements, conjugative plasmids and integrons. 
To characterize plasmid diversity among K. pneumoniae, 183 K. pneumoniae clinical isolates 
from Portugal were subjected to whole genome sequencing by a second generation platform (Illumina), 
and their plasmidome was characterized. Herein, IncFIB is the most prevalent replicon from the Inc 
family, with its prevalence showing a slight increasing trend over the last 20 years. Seven of these 
isolates, five of which classified as MDR, were further subjected to whole genome sequencing by a third 
generation platform (PacBio), producing long-read sequence data. In total, the complete sequence of 20 
plasmids was obtained. The majority of these plasmids carry genes coding for β-lactamases and 
aminoglycoside resistance. CTX-M-15 was the only ESBL enconded on a plasmid and it always found 
on a similar Tn3 transposon. Moreover, this study allowed the identification of blaLAP-1 on a K. 
pneumoniae isolate for the first time. To investigate the structural diversification of the plasmids herein 
characterized, we then compared their scaffold with the scaffold of a global datset of plasmids available 
at the pAtlas database. Our results show that IncFIB(K) plasmids are the most conserved Inc-type 
plasmids while simultaneously identifying the same plasmidic scaffolds across distinct genetic 
backgrounds and geographically distributed isolates. 
The mobilization of these drug resistance plasmids to other Gram-negative bacteria responsible 
for hospital-associated infections through conjugation and transformation was also assessed. IncF 
plasmids were successfully transferred by conjugation to Escherichia coli but not to Acinetobacter 
baumannii or Pseudomonas aeruginosa.. Additionally, the transfer of a ColRNAI plasmid to E. coli was 
possible by transformation. 
This study comprises the largest ongoing sequencing effort of K. pneumoniae clinical isolates 
from Portugal. We also demonstrate the horizontal transfer of ESBLs to other Enterobacteriaceae via 
efficient conjugation by megaplasmids harbouring a diverse genetic content. Moreover, we showed that 
the gene content of these plasmids, which is not limited to antibiotic resistance, can potentially 
contribute to high rates of persistence in its host strain even in the absence of the selective pressure of 
an antibiotic.  
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RESUMO 
Klebsiella pneumoniae é uma bacteria Gram-negativa pertencente à familia Enterobacteriaceae. 
Esta é responsável por um número significativo de infecções hospitalares em todo o mundo, afectando 
essencialmente grupos que compreendem, entre outros, indivíduos imunocomprometidos ou com certas 
outras infecções e doenças. Apesar de os antibióticos constituirem uma arma essencial para o combate 
deste tipo de infecções, a notável plasticidade genética destas bactérias leva à rápida emergência de 
estirpes resistentes a antibióticos. K. pneumoniae é uma bactéria frequentemente multi-resistente (MDR), 
isto é, resistente a três ou mais classes de antibióticos. O aumento da incidência de casos com infecções 
hospitalares envolvendo estirpes MDR produtoras de β-lactamases de espectro alargado (ESBLs) e 
carpabenemases constitui um motivo de preocupação crescente, já que estas se encontram associadas a 
elevadas taxas de morbilidade e mortalidade.  
A resistência a antibióticos pode estar associada a mecanismos intrínsecos, ou pode ser adquirida 
por mutações em genes no cromossoma associados ao mecanismo de acção de antibioticos ou pela 
transferencia horizontal de genes de resistência. Este último mecanismo é mediado por elementos 
móveis, dos quais se destacam os plasmídeos. Os plasmídeos podem ser transmitidos entre bactérias por 
conjugação (transferência de DNA mediada por canais que unem a célula dadora, com o plasmídeo, e a 
célula receptora, que recebe o plasmídeo) ou transformação (entrada de DNA livre no exterior da 
bactéria). A replicação dos plasmídeos é regulada pelo seu replicão, uma curta sequência de DNA com 
a origem de replicação e genes que codificam para proteinas envolvidas no início da replicação. No 
passado, pensava-se que as bactérias não podiam conter plasmídeos com o mesmo tipo de replicão, um 
fenómeno designado “incompatibilidade plasmídica” usado para a classificação de plasmídeos em 
vários grupos Inc; todavia, alguns estudos têm vindo a questionar este conceito. Certos grupos Inc são 
restrictos a espécies ou géneros de bactérias específicos, enquanto que outros apresentam uma maior 
amplitude quanto ao seu hospedeiro, podendo disseminar-se por várias famílias de bactérias. A 
sequência e estrutura do replicão, bem como a presença de vários replicões no mesmo plasmídeo 
(designados plasmídeos multireplicão) são os factores mais importantes na determinação do leque de 
hospedeiros capazes de albergar um plasmídeo. A diversificação e evolução dos plasmídeos é mediada 
por outros elementos móveis: transposões (sequências de DNA capazes de saltar de um ponto para outro 
do cromossoma, do cromossoma para o plasmídeo ou entre plasmídeos), transposões conjugativos (com 
característias estruturais e funcionais mistas dos plasmídeos e dos transposões) e integrões (responsáveis 
pela captura e integração de cassetes génicaspor eventos de recombinação). 
Por serem elementos importantes na evolução microbiana e na transferência de genes de 
resistência a antibióticos, o principal objectivo deste trabalho foi a análise e caracterização molecular de 
plasmídeos. Este estudo consiste no maior projecto de sequenciação de isolados clínicos de K. 
pneumoniae em Portugal. No total, 183 isolados de K. pneumoniae obtidos em diferentes hospitais de 
Lisboa ao longo de 36 anos foram sequenciados por uma plataforma de segunda geração (Illumina). 
Nesta fase inicial, averiguámos quais os replicões mais prevalentes, a sua distribuiçao temporal e a sua 
associação com certos STs. Os resultados obtidos mostram que o replicão IncFIB é o mais frequente na 
maioria dos STs destes isolados portugueses e reportam uma tendência para o aumento da sua 
prevalência nos últimos anos. Adicionalmente, estes resultados apontam para a forte disseminação 
temporal deste replicão em Portugal e em diversos STs. Por outro lado, outros replicões como IncR ou 
IncFII demonstram uma diminuição da sua prevalência ou valores estáveis ao longo do tempo.  
Posteriormente, sete isolados de STs distintos foram escolhidos para uma análise mais detalhada 
dos seus plasmídeos e do respectivo conteúdo génico através de sequenciação genómica completa por 
uma plataforma de terceira geração (PacBio). Cinco destes isolados são MDR e apresentam resistência 
concomitante à cefotaxima, mas nenhum mostrou ser resistente ao carbapenemo imipenemo. A 
assemblagem dos contigs foi realizada de duas formas: uma usando somente as reads obtidas por PacBio, 
e uma abordagem híbrida em que se combinaram as reads obtidas pelas duas plataformas de 
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sequenciação. Foram obtidos um total de 20 plasmídeos, maioritariamente comprendendo replicões do 
tipo IncFII(K) e IncFIB(K). Dois dos isolados contêm megaplasmídeos do mesmo grupo de 
incompatibilidade; tratam-se, porém, de plasmídeos que são multireplicão, e em ambos os casos estes 
replicões encontram-se associados a divergência nucleotídica e terão acumulado polimorfismos 
potencialmente envolvidos na alteração da especificidade dos mecanismos de incompatibilidade, ou 
simplesmente à sua inactivação. 
A maioria dos plasmídeos aqui estudados contém genes que codificam para proteínas 
membranares, sobretudo transportadores ABC e proteínas involvidas na mediação da conjugação. Para 
além destes, outros foram detectados, nomeadamente genes que codificam para proteínas fágicas, 
mobilização de ferro e resistência ao mercúrio. Quanto aos genes de resistência a antibióticos, as classes 
mais frequentemente encontradas são β-lactamases e proteinas de resistência aos aminoglicosídeos. 
Notavelmente, neste estudo foi descrita pela primeira vez a β-lactamase LAP-1 num isolado de K. 
pneumoniae; esta foi ainda a primeira detecção da enzima  LAP em Portugal. O contexto genético deste 
gene foi descrito neste trabalho, juntamente com o contexto genético dos genes arr-2, conferindo 
resistência ao antibiótico rifampicina a um dos isolados, e blaCTX-M-15, a única ESBL presente nestes 
plasmídeos e associada a um transposão Tn3 com uma estrutura semelhantte em todos eles. 
De seguida, a diversificação estrutural dos megaplasmídeos deste estudo foi estudada por 
comparação com plasmídeos da base de dados pAtlas, obtidos de isolados da família Enterobacteriaceae 
e de regiões geográficas diversas. Os nossos resultados mostram que os plasmídeos IncFIB são os mais 
conservados não só em Portugal mas noutras regiões do globo, o que nos diz que a vasta disseminação 
de resistência a antibióticos se encontrará intimamente ligada a plasmídeos com este replicão. Destaca-
se ainda a detecção de plasmídeos estruturalmente idênticos aos descritos neste estudo em diversas 
regiões geográficas e backgrounds genéticos, atestando assim o seu enorme potencial para a 
disseminação global de genes de resistência a antibióticos. 
Por forma a corroborar a capacidade destes megaplasmideos de se disseminarem em multiplos 
hospedeiros, foram realizados ensaios de conjugação entre dois dos sete isolados clínicos de K. 
pneumoniae e as seguintes bactérias de Gram-negativo: Acinetobacter baumannii, Escherichia coli e 
Pseudomonas aeruginosa. O único receptor que foi possível conjugar foi E. coli. Usando o primeiro 
dador, obtivemos três conjugantes, os quais ganharam resisência às cefalosporinas de terceira geração 
cefotaxima, ceftazidima, e ao β-lactâmico amoxicilina na presença no inibidor ácido clavulânico. 
Usando o segundo dador, obtivemos dois conjugantes, os quais ganharam resistência aos antibioticos 
cefotaxima, ceftazidima, ciprofloxacina, gentamicina, tetracilina, sulfametoxazol-trimetoprim e ao β-
lactâmico amoxicilina na presença do inibidor ácido clavulânico. No entanto, os níveis de resistência a 
estes antibióticos difere entre estes ultimos dois transconjugantes. Por forma a esclarecer estas 
diferenças, realizaram-se ensaios usando o inibidor de bombas de efluxo reserpina. Estes ensaios 
demostraram que as diferenças observadas não se devem exclusivamente a mecanismos de efluxo, uma 
vez que as reduções observadas ao nível das concentrações mínimas inibitórias de determinados 
antibióticos não foram significativas.  
Na fase final, procurámos estudar a estabilidade de alguns dos megaplasmídeos aqui 
caracterizados na ausência da pressão selectiva de um antibiótico. Os resultados obtidos demonstram 
que, apesar do seu tamanho e da ausência desta pressão, todos os isolados à excepção de um apresentam 
uma elevada estabilidade plasmídica. Estes resultados sugerem que o extenso conteúdo génico presente 
nestes megaplasmídeos poderá acarretar outras vantagens selectivas para o hospedeiro, contribuindo 
desta forma para a presença e persistência de genes de resistência a antibióticos na ausência de uma 
pressão selectiva e no meio ambiente. 
 
Palavras-chave: Klebsiella pneumoniae; Resistência a antibióticos; Plasmídeos; Transferência 
horizontal de genes.
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1. INTRODUCTION 
 
1.1 Klebsiella pneumoniae: an Emerging Healthcare-associated Pathogen 
Klebsiella pneumoniae is a Gram-negative, rod-shaped, non-motile bacillus that belongs to the 
Enterobacteriaceae family. This bacterium is facultatively anaerobic, oxidase-negative, catalase-
positive, lactose-fermenting and non-spore-forming1. It is usually encapsulated, this being one of the 
most important factors for virulence2,3, since it grants protection against phage predation, increases 
resistance to serum complement and it allows the bacteria to escapse the host’s inflammatory system 
(phagocytosis and macrophages/neutrophils intracellular killing)4–6. Aside the clinical settings, which 
represent a more recent ecological niche, K. pneumoniae can be found on the soil, sewage, surface waters, 
plants and animals7–10. In humans, the primary reservoir for this bacterium is mostly the gastrointestinal 
tract, although it can also be found in the nasopharynx, it being infrequent on the skin8.  
Although K. pneumoniae typically colonises humans’ mucosal surfaces without causing 
pathology11, it is responsible for a significant number of community-acquired infections worldwide12. 
Furthermore, Klebsiella-associated infections are strongly linked with hospitalization and elevated 
morbidity and mortality rates in hospital settings9,13, namely by causing nosocomial outbreaks and 
triggering a wide range of infections such as urinary infections, pneumonia, septic shock and 
meningitis6,14. The groups with higher risk of being infected by this opportunistic pathogen are mainly 
the neonates, the elderly, and immunocompromised individuals often with other severe underlying 
infections, certain comorbidities (like diabetes) or life-threatening diseases9,15,16. Additional risk factors 
that lead to the increase of K. pneumoniae infection rates include: previous antibiotic therapy, invasive 
procedures (tracheal intubation, central venous catheterization, surgery), blood transfusion and organ 
transplantation, the size of the hospital, the duration of hospitalization and patient readmission6,16–18. 
 
1.2 The Antibiotic Resistance Crisis 
1.2.1 Antibiotic Action Mechanisms  
In nature, bacteria and fungi produce chemicals to attack other microbes that compete for the 
same resources. These act by blocking or destabilizing processes or structures essential for microbial 
growth and survival. Antibiotics can be either bacteriocidal (if they kill bacteria) or bacteriostatic (if 
they interrupt bacterial growth)19. These drugs have three main targets: (1) cell wall synthesis, (2) nucleic 
acid synthesis and (3) protein synthesis20. The main class of antibiotics from the first group are β-lactams 
(penicillins, cephalosporins, monobactams, and carbapenems), which bind to cell wall synthesis 
enzymes, causing the disruption of the peptidoglycan coat and consequent bacterial lysis21,22. In the 
second group, fluoroquinolones inhibit the bacterial DNA gyrase, needed for bacterial replication to 
prevent excessive DNA positive supercoiling23. Other examples of antibiotics from this second group 
are sulfonamides and trimethoprim, which inhibit DNA synthesis by disrupting the cell’s folic acid 
metabolism24, and rifampicin, which inhibits the bacterial RNA polymerase, responsible for 
transcription25. In the third group, aminoglycosides and tetracyclines inhibit protein synthesis by 
blocking the ribosome’s 30S subunit22, while chloramphenicol interfers with the 50s subunit26; these 
three classes lead to premature termination of mRNA translation22. 
 
1.2.2 Antibiotic Resistance Mechanisms 
The notable genetic plasticity of bacteria allows them to respond to a wide array of 
environmental pressures; therefore, it only takes months to years after the start of the routine 
administration of a new antibiotic for resistant bacterial strains to rise27. For example, penicillin 
resistance was first detectef in the mid 1940s, only two years of its introduction28. Alarmingly, some 
studies have shown that, as the antibiotic resistance levels increase, the patients’ average survival time 
 2 
 
is shortened29,30. There are multiple forms of antibiotic resistance, falling either into the intrinsic or the 
acquired resistance categories19. 
Intrinsic resistance is based on the bacteria’s structural or functional characteristics and is a 
result of phenotypic changes without the uptake of additional genetic information; it can be a 
consequence of a reduced membrane permeability30. Gram-negative bacteria are naturally insusceptible 
to many antibiotics due to the presence of an outer-membrane; this factor, together with the saturated 
nature of the fatty acid chains within their lipopolysaccharide layer, contributes to a decrease of 
membrane fluidity and permeability in these bacteria31,32. Intrinsic resistance can also be granted by 
porins, nonspecific diffusion channels present on the outer-membrane that not only allow the entry of 
specific key nutrients but also block the influx of a number of antibiotics33. 
Antibiotics can also be expeled by efflux pumps, which keep the intrabacterial concentrations 
of certain drugs at low and not toxic levels by expelling them at a faster rate than they can enter the cell; 
for example, TET-resistant bacteria frequently overproduce efflux pumps34,35. These membranal 
structures can be specific for one drug or export a variety of molecules34. However, unlike what happens 
with TET, the action of efflux pumps in some antibiotics usually leads to low-levels of resistance, so, 
for higher resistance levels, bacteria typically depend on acquired resistance mechanisms, although this 
is not always the case34,35. 
Antibiotic resistance can be acquired either by the horizontal transfer of resistance genes or by 
spontaneous chromosomal mutations in genes associated with the antibiotic’s mechanism of action20,27. 
An example of the latter is quinolone resistance in Enterobacteriaceae23. Acquired resistance has many 
possible origins, such as the modification or degradation of the antibiotic’s active site. 
Enterobacteriaceae most commonly gain resistance to β-lactams by the acquisition of genes coding for 
β-lactamases, enzymes that neutralize the β-lactam ring before these antibiotics can reach the 
peptidoglycan coat22. In the 1980s, the increased prevalence of β-lactamases like TEM-1 e SHV-1 lead 
to the introduction of 3rd generation cephalosporins (like ceftazidime an cefotaxime) in hospital settings; 
this new selective pressure lead to the rapid rise of novel β-lactamases: Extended-Spectrum β-
Lactamases (ESBLs)36. These grant resistance to all β-lactams but carbapenems and cephamycins36,37. 
Modification or overproduction of the target enzyme can also lead to acquired resistance; for example, 
RIF resistant strains usually emerge due to specific mutations which are expected to decrease binding 
of the RNA polymerase to this drug38. Last but not the least, the acquisition of alternative metabolic 
pathways to those inhibited by the drug can lead to acquired antibiotic resistance20. 
 
1.2.3 K. pneumoniae: Antimicrobial Resistance in Europe 
K. pneumoniae strains are frequently multidrug resistant (MDR), that is, resistant to three or 
more classes of antibiotics39. The increasing emergence of MDR K. pneumoniae strains producing 
ESBLs and plasmid-encoded carbapenemases has become a major cause of concern worldwide due to 
the lack of alternative therapeutic options and the high morbidity and mortality rates associated with 
infections by these strains40-42. Antimicrobial inappropriate and irrational prescribing and overuse in 
clinical and food-producing settings, together with the absence of monetary incentives and the 
challenging regulatory requirements for the production of new antibiotics, has been stipulated to be the 
root of this antibiotic resistance crisis43–46. 
Data from the 2017 “Surveillance of antimicrobial resistance in Europe” report47 show that, in 
2017, 34.1% of the K. pneumoniae clinical isolates in Europe were resistant to at least one of the 
following four antimicrobial groups: fluoroquinolones, third-generation cephalosporins, 
aminoglycosides and carbapenems. The most common resistance phenotype in this study was the 
combination of resistance to fluoroquinolones, third-generation cephalosporins and aminoglycosides. 
Fluoroquinolones was revealed to be the class with the highest population-weighted mean resistance 
percentage (31.5%) and it was followed by third-generation cephalosporins (31.2%), aminoglycosides 
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(24.1%) and carbapenems (7.2%). Cases of clinical isolates resistant to at least two of these four groups 
were more comon than cases of single resistance. Figure 1.1 shows a substantial inter-country variability: 
countries on the south and east of Europe (Bulgaria, Greece, Poland, Lithuania, Romania, Slovakia and 
Italy) reported a higher resistance percentage to the four antimicrobial groups mentioned above when 
compared to northern european countries (Finland, Sweden, Norway and Denmark). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Distribution of K. pneumoniae isolates susceptible and resistant to fluoroquinolones, third-generation 
cephalosporins, aminoglycosides and carbapenems in EU/EEA countries, 2017. Adapted from: ECDC (2018)47. 
 
1.2.4 Emergence of ESBL and Carbapenemase-producing K. pneumoniae and 
Enterobacteriaceae 
ESBLs have become an important focus of attention over the last years. It is believed that the 
ESBL-spread phenomenon had its origins in Europe, most likely due to the selective driving forces of 
third-generation cephalosporins consumption, which began here36. Notably, in the ECDC report 
mentioned above47, 87.8% of the K. pneumoniae isolates resistant to third-generation cephalosporins 
were found to be positive for the presence of an ESBL. Once again, important geographical differences 
are evident: eight countries reported a statistically significant increase of K. pneumoniae clinical isolates 
resistant to third-generation cephalosporins from 2014 to 2017 (Finland, Netherlands, United Kingdom, 
Germany, Spain, Hungary, Portugal and Lithuania), while only three reported a decrease (Latvia, 
Romania and Slovakia). The distribution of K. pneumoniae isolates resistant to third-generation 
cephalosporins in Europe in 2017 is evident in Figure 1.2. Countries on the north report up to 99% of 
isolates susceptile to this class of antibiotics, while in the south-east regions of Europe the percentange 
of resistance can be higher than 50% . 
One of the most epidemiologic relevant ESBL in K. pneumoniae is the CTX-M family. In fact, 
in Europe there has been a significant rise of these β-lactamases and a decrease of the TEM and SHV 
variants in the past few years48. Theses β-lactamases are inhibited by clavulanate and tazobactam and 
grant high levels of resistance to CTX, while also conferring resistance to ceftriaxone and aztreonam49,50. 
Although Enterobacteriaceae carrying CTX-M β-lactamases have spread all over the world, eastern 
Europe, South America, and Japan are hot areas for their emergence51. During the 1990s, the same  
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CTX-M-like enzymes were isolated and identified for the first time in distant countries and continents 
– for example, CTX-M-1 was first detected in an Escherichia coli isolate from Japan in 1986 (this 
enzyme was originally named FEC-1)52 and in a K. pneumoniae isolate from California in 198753. The 
rapid and strong dissemination of these enzymes is probably dued to international travel51.  
A variety of ESBLs have been reported in K. pneumoniae isolates from Europe. On northern 
countries, the most commom ESBLs are from the CTX-M and SHV families48. In Spain, there is a 
notable higher prevalence of the enzymes CTX-M-9, CTX-M-14, CTX-M-10 and TEM-4; in Portugal, 
studies of individual hospitals report TEM, SHV and CTX-M-like ESBLs, and a predominant spread of 
CTX-M-14 and TEM-52, alongside with TEM-24, CTX-M-15, CTX-M-32 and SHV-12 which are 
commonly detected in both countries54–57. In Italy, TEM β-lactamases are the ESBLs most commonly 
reported, as well as CTX-M-1, -15 and -32; these enzymes are less predominant in K. pneumoniae than 
they are in E. coli58,59. ESBL-producing K. pneumonia in eastern Europe most commonly carry CTX-
M-3, but also SHV-2 and SHV-560–62. 
The CTX-M-15 enzyme seems to be wide-spread in almost all european countries51. This β-
lactamase grants resistance to ceftazidime, which is not the case for the majority of CTX-M-type β-
lactamases50,63. CTX-M-15 has been increasingly associated with community and hospital-acquired 
infections48,64–67. This enzyme was first isolated in India, in the year 200063. In Portugal, the first K. 
pneumoniae strain producing CTX-M-15 was isolated in 200368. The current CTX-M-15 pandemic 
dissemination is partially atributed to the E. coli strain O25:H4-ST131, which has been detected in the 
majority of european countries and has been found to harbour different plasmids, all of them carrying 
this enzyme69,70.  
Regarding carbapenem resistance driven by carbapenemase-producing bacteria, it is perceptible 
that resistance levels in K. pneumoniae have been increasing throughout the years. To better study this 
rise, the European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) developed the 
project “European Survey of Carbapenemase-Producing Enterobacteriaceae”71. Here, seven 
epideomological stages were established, ranging from Stage 0 (no cases reported) to Stage 5 (endemic 
situation). While in 2010 five of the participating countries were classified as stage 0 (Austria, Bulgaria, 
Estonia, Iceland and Slovenia), in 2018 all 37 countries from this study reported cases of infections by 
a carbapenemase-producing Enterobacteriaceae (Stage 1 or higher). From 2015 to 2018, 11 countries 
reported a worsening of the epidemiological stage (Bosnia and Herzegovinaa, Croatia, Cyprus, Czech 
Republic, Finland, Iceland, Ireland, Kosovo, North Macedonia, Portugal and Serbia), while only one 
country reported a decrease (Slovenia). No changes were described for the remaining 25 countries. 
Greece, Italy, Malta and Turkey reported an endemic situation both in 2015 and in 2018. The 
epidemiology of carbapenemase-producing Enterobacteriaceae in 2018 is described in Figure 1.3. K. 
penumoniae is the Enterobacteriacea where carbapenem-resistance is more predominant.47 
Figure 1.2. Percentage of K. pneumoniae invasive isolates with resistance to third-generation cephalosporins in 
EU/EEA countries, 2017. Adapted from: ECDC (2018)47. 
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In the countries that provided genotypic data to this study as to understand the underlying 
molecular basis of resistance, the most frequently detected carbapenemase genes were blaVIM, blaKPC, 
blaNDM and blaOXA-48, followed by blaIMP, blaGES, blaFRI, blaIMI and blaSME71. 
 
 
 
 
 
 
 
 
 
Figure 1.3. Epidemiological situation of carbapenemase-producing Enterobacteriaceae in 2018. Brolund et al. (2019)71. 
 
1.3 Plasmids in Enterobacteriaceae 
1.3.1 Plasmids are Important Vehicles for the Spread of Antimicrobial Resistance 
Plasmids are bacterial, circular DNA molecules capable of self-replication. Although they carry 
no genes indispensable for host cell’s growth when under non-stressed conditions, resistance genes 
located on plasmids grant a selective advantage to the bacteria under antimicrobial pressure72. Plasmids 
carrying antimicrobial resistance genes are a key vehicle for bacterial evolution since these promote the 
horizontal gene transfer between bacteria from different genera. This is particularly true when they carry 
multiple genetic markers that confer resistance to distinct classes of antibiotics, since this offers a 
selective advantage to the host when several antimicrobial drugs are simultaneously administered73. 
There are two possible ways for a plasmid to be taken up by bacteria, one being transformation 
– the stable and functional uptake, integration and expression of extracellular DNA by bacterial cells 
that previously reached a physiological state of competence under specific growth conditions74,75. Many 
genera of pathogenic bacteria are naturally transformable, competence being triggered by specific 
environmental changes like lack of nutrients or celular density, and sometimes being dependent on the 
growth-stage76,77. In lab settings, competence can be achieved with treatment with high concentrations 
of Ca2+ and heat shock74,78. Bacteria that are difficult to transform (due to the presence of thick cell walls 
or capsules, for example) or that are not naturally transformable can also be subjected to electroporation, 
a technique where cells are mixed with the DNA and then exposed to short high-voltage electrical pulses 
to permeabilize the cell envelope79,80. These procedures allow the cell to take up double-stranded DNA74. 
Another process for plasmid mobilization is conjugation. Plasmid conjugative transfer is mediated by 
cell-to-cell channels (pili) through which DNA can be transfered from the donor cell (containing the 
conjugative plasmid) to the recipient cell72. 
 
1.3.2   Plasmid Incompatibility Groups 
Plasmid replication is regulated by its basic replicon – a small sequence of DNA (typically not 
larger than 1.8 Kbp) that comprehends the ori (origin of replication) and other sequences coding for 
specific replication initiation proteins81-83. Bacteria can carry multiple plasmids; however, in the past it 
was belived that plasmids with the same replicon type could never coexist in the same cell, due to a 
phenomenon called plasmid incompatibility83. This is caused by a competition for factors involved in 
replication control and/or DNA equipartitioning during cell division, which inevitably gives a selective 
advantage to the plasmids that, for example, can replicate faster due to their smaller size or are less 
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toxic82,83. Plasmid incompatibility is also strongly related to another phenomenon, plasmid exclusion – 
the presence of certain membrane proteins preventing conjugation with a donor cell carrying the same 
plasmid. pTraT and pTraS are partially responsible for this, the first protein reducing the cell’s ability 
to form stable mating aggregates (surface exclusion) and the latter reducing DNA transfer within stable 
mating aggregates (entry exclusion)84. With the first formal system of plasmid classification, plasmids 
were sorted into distinct incompatibility (Inc) groups81. This classification method consisted on the 
transfer of a plasmid of an unknown Inc group into a bacterial strain carrying a plasmid of a previously 
identified Inc group. The plasmid that was being tested would be assigned to the same Inc group as the 
plasmid from the recipient strain if one of these molecules was eliminated in the population85. 
Recent studies question this concept of incompatibility by denoting the stable maintenance of 
plasmids harbouring the same origin of replication in a celular line86. During cell division, plasmids 
replicate and segregate within minutes to oposite polls of the cell; here, they may replicate once again87. 
The partitioning of plasmids from different Inc groups is independent and even happens at different 
times of the cell cycle, which is crucial for the cell to maintain both plasmids86,87. If replicons acumulate 
mutations in the genes responsible for this stochastic process of plasmid partitioning, the plasmid 
incompatibility specificity might be altered88. It has been theorized that this frequently happens in 
multireplicon plasmids, where one replicon is strongly conserved while the other tends to diverge. 
Mutations in one of the replication initiation genes can even lead to the emergence of a novel replicon 
and, consequently, changes in replicon incompatibility88.  
In 1988, a new plasmid classification method was developed, based on the recognition of the 
basic replicons frequently found on Enterobacteriaceae using hybridization tecniques82. Since those old 
plasmid identification systems were time-consuming and non-pratical for large scale analysis, Caratolli 
and collegues developed a PCRbased replicon typing (PBRT) technique, a more efficient, fast and 
inclusive method of plasmid classification. 18 pairs of primers were designed to perform five multiplex 
and three simplex-PCRs89, recognizing the most representative Inc groups circulating among 
Enterobacteriaceae: IncFIA, FIB, FIC, HI1, HI2, I1-Ig, L/M, N, P, W, T, A/C, K, B/O, X, Y, F, and 
FIIA82. PBRT was later improved with the implementation of real-time PCR, wich made this tecnique 
faster and more sensitive to the detection  of low-copy plasmids90.  
Considering how these classification methods focus solely on the classic and most common 
replicons, it is clear that they fail to detect divergent or novel replicons. In order to complete the typing 
and classification of all the plasmids circulating in Enterobacteriaceae, other replicons should be cloned 
and sequenced89. Additional big challenges for plasmid replicon typing are multireplicon plasmids and 
the fact that some plasmids can cointegrate, originating, by recombination events, a new multireplicon 
that might not be easily detected91–93. Therefore, the most accurate methodology to characterize a 
plasmid is by subjecting its full-length DNA sequence to new-generation sequencing and then 
annotating its resistance and virulence genes, as well as its replicon(s) using PlasmidFinder. 
PlasmidFinder is an online plataform with a  database built on plasmid replicon sequences obtained from 
a total of 559 fully sequenced Enterobacteriaceae plasmids available on the NCBI database94. 
 
1.3.3 Plasmid Diversity in Enterobacteriaceae 
IncF, IncI, IncA/C and IncH are some of the most common replicons in Enterobacteriaceae in 
Europe, Asia and the Americas95. Their distribution is summarized in Figure 1.4, and the antibiotic 
classes most frequently found on these plasmids is summarized in Figure 1.5. 
IncF are large (>100 Kbp) low-copy-number conjugative plasmids that can harbour more than 
one replicon – usually FII together with IncFIA or FIB, or other replicons with a broader host range (a 
concept discussed in 1.3.5)92,95. The antibiotic resistance genes most frequently found on IncF plasmids 
code for ESBLs and other β-lactamases (in particular blaTEM, blaSHV, blaCTX-M and carbapenemases), 
aminoglycoside-modifying enzymes and quinolone resistance48,95.  
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Figure 1.4. Distribution of different Inc groups isolated from human, animal and environment in Europe, Asia and the 
Americas. “Other”: ColE, IncB/O, IncK, IncL/M, IncN, IncP, IncR, IncT, IncU, IncW, IncX, IncY and IncZ. Adapted from: 
Rozwandowicz et al. (2018)95. 
 
 
 
 
 
 
 
 
 
Figure 1.5. Distribution of genes encoding resistance to different antimicrobial classes carried by the most frequent Inc 
types: IncF, IncI, IncA/C and IncH. The “Other” antibiotics group includes genes encoding resistance to: trimethoprim, 
chloramphenicol, florfenicol, colistin, fosfomycin. Adapted from: Rozwandowicz et al. (2018)95. 
 
CTX-M-15 spread is highly associated with IncF plasmids, mainly the subtype IncFII95,96. The 
blaCTX-M-1 gene is commonly carried both on IncN and IncI1 plasmids73,98. In Spain the United Kingdom, 
IncK plasmids have been linked with CTX-M-14 dissemination, while in Asia the gene coding this 
enzyme is typically found on IncF plasmids99–101. CTX-M-3 disseminated in Europe and China in a 
conjugative plasmid from the IncL/M family95. Genes coding for carbapenemases are mostly found on 
the following families: IncL/M, IncA/C, IncF, IncHI1, IncX3 and novel IncN and IncHI1 variations, as 
well as the rare IncT family73. oqxA and oqxB, coding for efflux pumps, have been identified on an 
IncX1 plasmid, as well as on IncF plasmids in E. coli isolates from China and Eastern 
Europe102,103.  Regardless of these trends, it is clear that most of these antibiotic resistance genes have a 
notable potential for the spread among a large repertoire of plasmids95. 
Although the high prelavence of these plasmids is strongly linked to an antibiotic selective 
pressure, their distribution is ubiquitous95,104. The presence of virulence factors in association with 
resistance genes in plasmids provides a strong selective advantage73,105. For example, the existence of 
virulence clusters on the scaffold of some IncF plasmids might explain their spread among 
Enterobacteriaceae in the ausence of an antibiotic pressure106,107; IncI1 plasmids have also been found 
to carry genes coding for type IV pili, contributing to adhesion and bacterial invasion107.  
 
1.3.3.1 Plasmid Diversity in K. pneumoniae 
The PCR-based replicon typing method mentioned above did not allow the typing of most 
K. pneumoniae plasmids89. However, with the advances in genomics and whole-genome sequencing, 
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the complete sequencing of K. pneumoniae plasmids is now possible. The plasmids carried by this 
bacterium are generally from the IncF family, in particular IncFII. FIIk, the most frequent replicon 
identified in K. pneumoniae, is often linked with replicons of the FIB-type. FIBpKPQIL and FIBpKPN 
are the FIB-type replicons more recurrently reported in K. pneumoniae plasmids109. Plasmids 
harbouring the pKPN-CZ variant have been found to carry blaCTX-M-15 and type 3 fimbriae110. However, 
blaCTX-M genes on Klebsiella isolates are typically located on plasmids that are very similar to E. coli 
plasmids and that differ from the ones carrying blaKPC. Multireplicon plasmids carrying IncFIIk and 
IncR/IncN are als common in K. pneumoniae, these being linked with the spread of blaKPC-2 in Italy, 
USA, China, Russia and Taiwan111. The blaKPC-2 and blaKPC-3 genes have also been linked with 
IncFIIkpKpQIL plasmids112,113. 
Another class highly represented in K. pneumoniae is Col-Like plasmids, in particular 
ColRNAI73,114. Bacteria usually carry around 20 copies of these small plasmids (around 6–40 Kbp) per 
cell95. These highly mobilizable vectors have mostly, but not exclusively, been associated with 
carbapenem and quinolone resistance in K. pneumoniae and other Enterobacteriaceae114-116. 
 
1.3.4   Plasmid Cross-species Compatibility 
Certain plasmids can only replicate and be stably maintained under specific conditions tailored 
to a few species (narrow-host range plasmids), while others are promiscuous and have the capability to 
replicate in a medium or broad range of hosts117. The IncF family is restricted to Enterobacteriaceae, 
while IncA/C, IncL/M, IncP, IncQ, IncR, IncU and IncW plasmids have a broad range of bacterial 
hosts95. Plasmid transfer between bacteria from different species, genera or families can be limited by 
factors such as interactions at the cell surface blocking conjugative contact, DNA degradation by the 
new host’s restriction systems or the absence of the machinary needed for plasmid replication in the new 
host118. Other factors incluce G+C content, oligonucleotide frequencies and codon usage119. 
The determination of the plasmid’s host range is frequently dictated by the structure of its origin 
of replication117. The precise coordenation of replicon recognition and the initiation of replication is 
depended on the origin’s nucleotide sequence, on the presence of specific proteins recognizing specific 
sites at the ori and modifying its DNA structure, and on the presence of DNA tertiary structures at the 
origin118. Some plasmids, like the ones from the broad-host range family IncQ, seem to be independent 
from the host for replication, and this is a key factor for their maintenance in many baterial hosts. These 
types of plasmids often proceed with the first priming step by carrying genes coding for their own 
primases (RepA, RepB and RepC)117,120. On the other hand, ColEl-type plasmids can only partially 
replicate in Pseudomonas spp. when the medium is supplemented with the purified E. coli enzymes 
gyrase and DNA polymerase I118. 
Overreplication or runaway (uncontroled) replication of low-copy-number plasmids has been 
proven to lead to the death of the bacterial host121,122. Therefore, failure in keeping the replication 
frequency in a low level is another explanation for the inability of narrow-host range plasmids to 
replicate in certain hosts118. The existence of several replication origins in multireplicon plasmids is also 
a factor that can play in favour of their broad-host range, if the different replicons are functional in 
different hosts116. For example, Da SilvaTatley and Steyn identified a plasmid that harboured a pUC1-
like and an IncF-like replicon, both active and functional in distinct bacterial hosts123. 
 
1.3.5  Mobile Genetic Elements as Drivers of Plasmid Diversification 
Antimicrobial resistance genes can be mobilized between bacteria through the acquisition of 
mobile elements in conjugative plasmids72,124.  
Transposable elements, one type of mobile elements, are considered to be "jumping genes", 
since they are able to move (“jump”) from one location to another in the genome, either within a plasmid 
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or the chromossome, or between these two molecules124. Insertion sequence elements (IS), short 
sequences of DNA (0.5–2 Kbp) coding for a transposase, are the simplest example of a transposable 
element125. Similar to ISs, ISCR elements are small mobile elements exhibiting a rolling circle 
mechanism for transposition and recombination126. Another type of transposable elements are 
transposons, which typically consist of a pair of an IS element and a central DNA feature which 
expression changes the cell phenotype124. Transposition requires the ends of the transposon to be flanked 
by the same IS element (usually short inverted repeats) and the presence of a transposase, an enzyme at 
the end of a transposon that catalyzes this event of transposition125. Some well-studied transposons 
found in Enterobacteriaceae are the Tn3 transposon (associated with β-lactam resistance), the Tn5 
transposon (encoding resistance to the aminoglycosides kanamycin and neomycin, among others), the 
Tn10 transposon (encoding tetracycline resistance) and the Tn21 transposon (linked with resistance to 
streptomycin, spectinomycin, sulphonamides and often containing the mercury resistance operon)124,125.  
Conjugative transposons are transposon-like elements, but these have a distinct method of 
excision and integration. These also combine features of plasmids, since after excision they form a 
closed circular structure; however, unlinke plasmids, these do not replicate. After excision, conjugative 
transposons will either integrate in another part of the chromosome or br transfered to other cells by 
conjugation to then integrate into the recipient's genome127. 
 Finally, integrons are another type of mobile elements that, unlike transposons, are based on 
site-specific recombination by an enzyme called integrase124. The amino acid sequences of the gene 
coding for these enzymes is what allows integron classification – class 1 Integrons carry intI1, class 2 
intI2, class 3 carry intI3, and class 4 carry intI4128. The first class, whose structure is represented in 
Figure 1.6, is the most commom. Integrons usually carry gene cassettes, small DNA sequences with a 
single gene (that can code for antibiotic resistance, for example) and a recombination site129. 
 
 
 
 
 
 
Figure 1.6. Schematic representation of a class 1 integron. The integron conserved region comprises the integrase gene intl1 
(coding for the enzyme responsible for integration), as well as an integration site (attI1) and promotors (P1 and P2) for the 
transcription of the genes on the variable region of the integron (“Resistance gene 1” and “Resistance gene 2”). The arrows 
represent the direction of transcription. The attC regions are the recombination sites. qacE∆1 and sulI confer resistance to 
quaternary ammonium compounds and sulfonamides. Adapted from: Carattoli (2001)128. 
 
1.4. Objectives 
The primary goal of this study relies in the molecular characterization of plasmids, particularly 
megaplasmids (>100 Kbp) associated with MDR K. pneumoniae isolates. This study encompasses 
clinical isolates obtained from different hospitals in Portugal, in the Lisbon region, over a time span of 
36 years. Second and third generation NGS data was obtained for these isolates with the aim of 
understanding plasmid diversity and their overall genetic plasticity under a global context. The specific 
objectives were:   
✓ To characterize the gene content and genetic environment of plasmid-associated drug resistance 
genes, as well as their contribution to horizontal transfer of drug resistance; 
✓ To study the mobilization of Klebsiella pneumoniae drug resistance plasmids to other Gram-
negative bacteria responsible for hospital-associated infections through conjugation and 
transformation. 
✓ To investigate the stability of studied plasmids in its host bacterial isolates in the absence of 
antimicrobial selective pressure; 
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2. MATERIALS AND METHODS 
 
2.1. Clinical Isolates and Gram-Negative Strains Used 
The initial part of this study includes a total of 183 K. pneumoniae clinical isolates collected in 
four different hospitals and laboratories in Lisbon over a period of 36 years, between 1980-2016. Then, 
from these, seven representing different sequence types (listed on Table 2.1) were studied more in depth. 
 
Table 2.1. K. pneumoniae isolates used in this study. 
Clinical Isolate Origin Biological Sample Year Genome length (bp) ST 
KP1208 Hospital A Urine 2006 5631566 35 
KP1264 Hospital A Blood 2007 5495084 147 
KP1363 Hospital B Blood 2005 5580655 16 
KP1675 Hospital B Blood 2008 5787724 48 
KP2209 Hospital A Urine 2008 5937559 133 
KP2958 Hospital A Blood 2010 5727377 14 
KP3860 Hospital A Blood 2013 5764368 397 
 
The E. coli isolates CF604 (harbouring a pCFF14 plasmid) and CF804 (harbouring a pC804 
plasmid) were used together with the seven isolates from Table 2.1 for plasmid extraction. 
RIF-resistant spontanous mutants named 1.1 (previously obtained from other studies from 
Acinetobacter baumanni ATCC19606 (S531F), E. coli ATCC25922 (S540Y) and Pseudomonas 
aeruginosa ATCC9997 (D521G)) were chosen as recipients in conjugation assays. E. coli BL21DE3 
(F– e14– (McrA–) hsdR (rK– mK–) glnV44 thr-1 leuB6 thi-1 lacY1 fhuA21 mcrB hflA150::Tn10 (TetR)) 
was used for transformation assays.  
 
2.2. Culture Media and Solutions 
The culture media, solutions and antibiotics used are listed on Supplementary Tables 5.1 to 5.4. 
 
2.3. Isolation of Genomic DNA from K. pneumoniae and Whole Genome Sequencing 
The DNA of 183 K. pneumoniae clinical isolates was extracted using a protocol from Soolingen 
et al. (1999)130.  
The bacteria were incubated overnight in LB Agar at 37°C, and at least one loopful of culture was 
transfer into 400 µL of TE (1×). The bacterial suspensions were heated at 90°C for 20 minutes and 
cooled down at room temperature. Then, 5 µL of lysozyme (10 mg/mL) were added and mixed by 
vortexing before an incubation step a 37°C for at least 2 hours, and 75 µL of Solution A were added and 
mixed by slowly vortexing before another incubation step for 10 minutes at 65°C. Afterwards, 100 µL 
of a 5M NaCl solution and 100 µL of a prewarmed (65°C) CTAB/NaCl solution were added sequentially. 
The mixtures were vortexed until they became white and incubated for 10 minutes at 65°C before adding 
750 µL of Solution B. After vortexing it again for a few seconds, this mixture was centrifuged (20 
minutes, 16000g, room temperature). The supernatants were carefully transferred to sterile eppendorfs. 
Then, 450µL of isopropanol were added before storing the extracted DNAs at -20°C overnight. The next 
day, the DNAs were centrifuged (15 minutes, 16000g, 4°C). Most of the supernatant was removed and 
1 mL of ethanol (70%) was added and mixed by turning the eppendorfs a few times upside down. After 
a final centrifugation step (5 minutes, 16000g, 4°C), most the supernatant was discarded and the 
remaining ethanol was removed with a pipette. To make sure there was no residual ethanol left on the 
DNA pellets, the eppendorfs were left with the lid opened for 5 to 10 minutes. The pellets were diluted 
in 100 μL of double-distilled water. 
The genomic DNA obtained was sequenced in an Illumina HiSeq 4000 platform and a PacBio 
RSII platform in the Genome Institute of Singapore as part of a collaboration between Faculty of 
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Pharmacy of the University of Lisbon, London School of Hygiene and Tropical Medicine and Genome 
Institute of Singapore. 
 
2.4. Plasmid DNA Extraction and Visualization by Agarose Gel Electrophoresis 
Plasmid DNA was extracted from the seven K. pneumoniae isolates from Table 2.1 and the E. 
coli isolates CF604 and CF804 using a protocol adapted from Birnboim and Dolly (1979)131. 
The bacteria were were grown overnight in LB Agar and then 1.5 mL of culture were centrifuged  
(13000g, 4 minutes, room temperature). The pellets were gently ressuspended in 100 μL of Solution I,   
placed on ice for 30 minutes, after which 200 μL of Solution II was added and gently mixed. After a 
second ice incubation for five minutes, 300 μL of Solution III was added and gently mixed, followed by 
a centrifugation step (15000g, 5 minutes, 4°C) and transfer of the supernatants to sterile eppendorfs. 
Afterwards, 1 mL of ethanol (97%) was added to the collected supernatants and the mixtures were 
incubated at -20 ºC over-night, after which DNA pellets were collected by centrifugation (15000g, 10 
minutes, 4°C) and washed in cold ethanol (70%). After another centrifugation step (15000g, 3 minutes, 
4°C), ethanol was carefully removed and the pellets dilluted in 100 μL of DDW.  
Plasmid DNA was visualized by agarose gel electrophoresis of 45 μL of each DNA samples, 
which ran for approximately 17 hours in a 0.7% agarose gel (routine grade agarose, Nzytech) made with 
TAE 1× at 60V and 4°C. The gel was stained after the run, by immersing it on 200 mL of TAE 1x 
containing 0.5 µg/ml of Ethidium Bromite (BioRad). 
 
2.5. Bioinformatic Analysis of NGS Data 
PacBio sequencing reads were assembled using the Pacific Biosciences SMRT Analysis Server 
portal and the therein implemented Hierarchical Genome Assembly Process (HGAP). Illumina 
sequencing data was de novo assembled using SPAdes assembler implemented on the Unicycler pipeline 
for optimization of best k-mer values, contig correction and rotation 
(https://github.com/rrwick/Unicycler). Short and long read data obtained by Illumina and PacBio were 
also assembled using Unicycler using a hybrid assembly approach by bringing short read based contigs 
using long read sequence data. The sequence types were determined using the pubMLST portal 
(https://pubmlst.org/kpneumoniae/). 
Plasmid replicons and drug-resistance genes were initially detected  using PlasmidFinder and 
ResFinder, available at “Center for Genomic Epidemiology” (http://www.genomicepidemiology.org/). 
Only the plasmids which replicons had a coverage equal or bigger than 60% and a percentage of identidy 
of at least 95% were considered (except for Col-Like plasmids, for which the cutt-of for the percentage 
of identidy was 80%)94. Screening for drug resistance genes was complemented with AMRFinder 
(https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/) and the NCBI Bacterial 
Antimicrobial Resistance Reference Gene Database (Accession PRJNA313047). The circularized 
contigs were annotated using RAST (http://rast.nmpdr.org/). BRIGG software (BRIG-0.95-dist) and 
Mauve (v. 20150226 10 (c) 2003-2015) were used for plasmid homology comparison. Easyfig (v. 2.2.3) 
was used for creating comparative physical maps. 
A global replicon-based phylogenetic analysis was carried out by comparing plasmid sequences 
herein obtained against  199 IncFIA, 891 IncFIB and 562 IncFII plasmid sequence downloaded from 
the pATLAS database (http://www.patlas.site). Downloaded sequences were mapped against reference 
plasmid sequences obtained in this study using Snippy with the -ctgs option. SNPs were extracted from 
VCF files, coverage validated and concatenated into a pseudo-molecule alignment where its position 
represent a homologous position across the entire dataset. jModeltest (2.1.10 v20160303) was used for 
statistical selection of best-fit models of nucleotide substitution and Seaview (v 4.6) was used for the 
construction of the phylogenetic trees. 
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2.6. Drug Susceptibility Testing and Minimum Inhibitory Concentration (MIC) Assays  
Drug susceptibility testing was carried out by Kirby-Bauer disk diffusion methods and/or 
determination of MICs, using the EUCAST guidelines and clinical breakpoints for phenotypic 
classification132. For disk diffusion assays, bacterial suspensions adjusted to a 0.5 McFarland standard 
were spread onto MHA plates, antimicrobial-impregnated disks placed on the surface of the agar, 
followed by an incubation at 37°C. Zone diameters were measured the following day. MIC assays were 
carried out on solid medium and/or by broth microdilution. For MIC determination on solid medium, 
bacterial suspensions were plated in LB or Drigalski Agar with various concentrations of each antibiotics 
as appropriate, plus a plate with no antibiotic (positive control). MIC determination by broth 
microdilution was performed on 96-well plates by inoculating 100 μL of MHB containing serial twofold 
dilutions of the antibiotic tested, with 10 μL of a 0.5 McFarland standard adjusted bacterial suspension. 
All plates were incubated at 37 °C and examined the next day. The MIC change in the presence of 
reserpine (an efflux pump inhibitor) was carried out at a concentration of 80 µM. The concentration 
ranges used for each antibiotic and for reserpine in MIC assays are listed in Table 2.2.  
 
Table 2.2. Range of concentrations tested in the MIC Assays. Antibiotic/reserpine concentrations: µg/mL. NT: not tested. 
Antibiotic 
Concentrations tested in the MIC Assays 
MIC on solid medium MIC by broth microdilution 
AMK (amikacin) NT 2 – 128 
AMX (amoxicilin) NT 1 – 1024 
CAZ (ceftazidime) NT 0.06 – 64 
CIP (ciprofloxacin) NT 0.015 – 16 and 1 – 64 
CTX (cefotaxime) 2 – 64 NT 
GME (gentamicin) NT 0.5 – 32 
KAN (kanamycin) NT 0.5 – 512 
RIF (rifampicin) 12.5 – 100 NT 
STR (streptomycin) NT 4 – 256 
TRIM (trimethoprim) NT 0.015 – 16 
Reserpine NT 3.1 – 100 
 
2.7. Conjugation Assays  
Conjugation assays were performed by mixing equal amounts of the donor and recipient strains 
with the same incubation times. Conjugation was carried out overnight at 37°C on solid  and liquid LB 
medium (the latter with no agitation). Transconjugants were selected by plating 100 μL of each 
conjugation mix on the appropriate medium and antibiotic concentration: Drigalski Agar containing 
CTX (64 µg/mL) and RIF (100 µg/mL) for A. Baumannii e E. coli recipients, and Cetrimide Agar with 
the same antibiotics when using P. aeruginosa as the recipient strain. These concentrations were chosen 
based either on the results of MIC assays or on ECOFF distributions from EUCAST132. The 
transconjugants were isolated in Drigalski Agar and subjected to the urease test. In short, a loopful of a 
pure culture was inoculated on Stuart’s Urea Broth and the test tubes were incubated at 37°C for 18 to 
24 hours. The medium remains yellow in negative tests and turns pink in positive tests. 
 
2.8. Transformation Assays  
Two transformation methods were used: transformation by heat shock and electroporation. The 
antibiotics used for transformant selection were as follow:  Kp1264 (RIF, 100 µg/mL), Kp1675 (STR, 
64 µg/mL), Kp2209 (CTX, 64 µg/mL) and Kp2958 (TET, 20 µg/mL). These antibiotic concentrations 
were chosen based either on the results of MIC assays or on ECOFF distributions from EUCAST132. 
Transformation with pUC19 was used as control for cell competence with transformants selected in LB 
Agar supplemented with ampicilin (100 μg/mL). 
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2.8.1. Preparation of Competent Cells using CaCl2 and Transformation by Heat Shock  
E.coli BL21DE3 was inoculated on LB Broth supplemented with MgSO4 (200mM, Fisher 
Bioreagents) with vigorous agitation until the culture reached an optical density at 590nm of 0.375. 
Then, the culture was poured into 50 mL falcons. These were placed on ice. From this point on, the cells, 
solutions and other material used must be kept ice cold. After a centrifugation step (3200g, 10 minutes, 
4°C), the pellet was ressuspended in 10 mL of CaCl2 (0.1 M, Fisher Bioreagents). The centrifugation 
and ressuspension steps were repeated three times. After the last centrifugation, the pellet was suspended 
in CaCl2 (0.1 M) supplemented with glycerol (10%, Fisher Bioreagents). Aliquotes were kept at -80°C 
for the transformation assays. 1 μL of the the previously extracted plasmid DNA was added to each 
suspension of competent cells and mixed by swirling. Tubes were placed on a 42°C water-bath for 90 
seconds and then rapidly transferred to an ice bath for one to two minutes. The cells were incubated for 
45 minutes at 37°C in 250 μL of SOC medium. Then, they were plated on LB Agar with the appropriate 
antibiotics for transformants selection.  
 
2.8.2. Transformation by Electroporation 
E. coli BL21DE3 was incubated until the culture reached an OD600nm of 0.8-1. The cells were 
placed on ice. From this point on, the cells, solutions and other material used must be kept ice cold. 
After a centrifugation step (320g, 10 minutes, 4°C), the pellet was ressuspend in 10 mL of glicerol. The 
centrifugation and ressuspension steps were repeated three times. After the last centrifugation, the pellet 
was ressuspend in the residual glycerol and aliquoted. Afterwards, 1 μL of the the previously extracted 
plasmid DNA was mixed with the cells, and this mix was transferred to a electroporation cuvette. The 
electroporation conditions were as follow: 1800 V, 200 Ω, 25 µF. The cells were incubated for 45 
minutes at 37°C in 250 μL of SOC medium. Then, they were plated on LB Agar with the appropriate 
antibiotics for transformants selection.  
 
2.9. Amplification of a Conserved Region of blaCTX-M-15  
DNA was obtained by boiling bacterial suspensions at 100°C for 10 minutes, followed by a 
centrifugation step at 13000g for 1 minute. The supernatant obtained was used for the amplification of 
a blaCTX-M-15 conserved region. Each 25-μl PCR mix contained 5 μl of template DNA, 1 U of NYZTaq 
DNA polymerase, DNTPs (200 μM each), 2.5 mM of MgCl2 and 400 μM of each primer, in 1× PCR 
buffer. The amplification profile was the following: initial 5-min denaturation step at 94°C; 30 cycles 
of 94°C denaturation for 30 seconds, 53°C annealing for 30 seconds and 72°C elongation for 30 seconds; 
and a final 10-min elongation step. For PCR amplification, the primers CTX-M-1F 
(ATGGTTAAAAAATCACTGCGyC)133 and CTX-M-1R (TTACAAACCGTGGTG)133 were used. 5 
μL of each PCR product ran for approximately 45 minutes in a 150 mL 1.5% agarose gel (routine grade 
agarose, Nzytech) made with TAE 1× at 150V, which was previously stained using 7 µL of GreenSafe 
Premium (NZYTech). 
 
2.10. Plasmid Stability Assays 
The stability of the megaplasmids from this study was determined in four clinical isolates and 
using the following antibiotic concentrations: Kp1264 (RIF, 100 µg/mL), Kp2209 (CTX, 64 µg/mL), 
Kp2958 (TET, 20 µg/mL) and Kp3860 (CTX, 64 µg/mL). These isoates lwere incubated at 37°C in LB 
Broth supplemented with the antibiotics listed above. Then, 100 μL of a 10-6 dilution were transferred 
into LB Broth at approximately 40-generation intervals (approximately 17 hours) over a 10 day period 
(10 cycles). For each cycle, the bacterial culture was plated on LB Agar and, by replica plating, on LB 
Agar supplemented with the most suitable antibiotic. The percentage of plasmid loss was calculated by 
dividing the number of colonies that grew with antibiotic by the viable count on LB Agar plates. This 
experiment was carried out in triplicate. 
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3. RESULTS AND DISCUSSION 
 
3.1. The plasmidome of K. pneumoniae in Portugal is Diverse but Dominated by IncFIB-Type 
and ColRNAI Replicons 
To investigate the plasmidome diversity associated with K. pneumoniae clinical isolates in 
Portugal, we de novo assembled the genome of 183 K. pneumoniae isolates from short-read sequence 
data obtained by Illumina paired-end sequencing. Using the PlasmidFinder database to screen for 
plasmid replicons within these contigs, we were able to detect a total of 863 hits, 683 of which fulfill 
the previously defined cut-off criteria (see Methods). From these, 414 Inc (distributed across 12 groups) 
and 269 Col-Like replicons (4 groups) were identified. Briefly, in the Inc family, IncFIB is the most 
prevalent replicon (n=164; 39.42%), followed by IncR_1 (n=70; 16.83%), IncFIA (n=64; 15.38%) and 
IncFII (n=42; 10.34 %). As for the Col-Like replicons, ColRNAI is present in approximately two-thirds 
of these plasmids (n=180) (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Prevalence (%) of (A) Inc and (B) Col-Like Replicons in 183 K. pneumoniae clinical isolates from Portugal.  
 
Since isolation dates of these K. pneumoniae isolates span across 36 years, we sough to 
investigate any specific trend regarding the prevalence of these plasmids (Figure 3.2). The prevalence 
of most Inc plasmids seems to remain rather stable throughout the years. However, for IncFIB there 
seems to be slight increasing trend over the last decades (from 33.3% to 53.7%), whereas the prevalence 
of IncR plasmids appears to show the opposite trend in the same time period (from 33.3% to 16.1%). 
IncFII plasmids were more frequent in the 80s (20.4%), but their prevalence declined in the 90s and 00s 
(~3%) before a more recent increase (12.8%). 
 
 
 
 
 
 
 
  
 
Figure 3.2. Distribution of replicos from 12 Inc groups throughout the years.  
 
Moreover, some replicons seem to be ST-associated (Table 3.1). ST35, 307 and 336 only 
harbour IncF plasmids from the IncFIB family. The latter is distributed among all but seven STs (ST20, 
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ST218, ST726, ST1728, ST826, ST920 and ST2176) and is usually the most prevalent IncF family 
replicon. An exception pertains ST15, where the prevalences of IncFIB, IncFIA, IncFII and IncR are 
similar (Table 3.1). IncX plasmids have only been found on ST25 and ST147 strains, while the IncA/C 
replicon is only observed among ST29, ST39 and ST92 isolates. IncL/M and IncY plasmids is only 
detected on one ST each (ST218 and ST231, respectively).  
 
Table 3.1. Distribution of Inc-type replicons on 183 K. pneumoniae isolates from 37 STs. The numbers in brackets represent 
how many replicons from that Inc group were detected in isolates from that ST, and the total of Inc-type replicons on that ST. 
Replicon ST 
IncFIB 
ST11 (5/5), ST12(4/8) ST13(3/4), ST14(8/15), ST15(49/202), ST17(1/3), ST25(5/15), 
ST29(1/3), ST30(1/2), ST35(2/2), ST37(2/3), ST39(2/7), ST43(1/1), ST45(4/6), 
ST48(1/3), ST70(3/4), S76(1/2), ST92(1/3), ST133(2/3), ST146(8/16), ST152(1/3), 
ST231(1/11), ST252(3/4), ST333(2/3), ST307(24/24), ST336(9/9), ST348(3/4), 
ST405(1/1), ST423(1/4), ST1801(1/1) 
IncFIA 
ST3(1/1), ST14(1/15), ST15(39/202), ST25(4/15), ST30(1/2), ST39(2/10), ST45(27/6), 
ST132(1/3), ST152(1/3), ST231(4/11), ST333(1/3), ST825(1/2), ST2176(1/2) 
IncFII ST13(1/4), ST14(1/15), ST15(34/202), ST48(1/3)  
IncN ST20(2/3), ST25(5/15), ST70(1/4), ST147(1/16), ST252(1/4), ST423(1/4), ST960(1/1) 
IncR ST14(3/15), ST15(49/202), ST39(2/7), ST48(1/3), ST147(1/16) 
IncH ST15(34/202), ST37(1/3), ST895(1/2), ST2176(1/2) 
IncFII ST13(1/4), ST14(1/15), ST15(34/202), ST48(1/3)  
IncQ ST14(1/4), ST48(1/3), ST147(1/16) 
IncA/C ST29(1/3) ST39(1/7), ST92(1/3) 
IncX ST25(1/15), ST147(1/16) 
IncL/M ST231(2/11) 
IncY ST218(1/1) 
 
The coexistence of IncF plasmids with broad-range plasmids (IncA/C, IncL/M, IncQ and IncQ) 
is of special concern since these can mediate the dissemination of antibiotic resistance and virulence 
genes to/from other Gram-negative bacteria phylogenetically distant from K. pneumoniae. 
 
3.2. Long-read Sequencing Enables Plasmid Structural Analysis 
Due to the inability to fully characterize and phase the gene content of each plasmid into a single 
sequence, the plasmids of seven of the previously sequenced isolates were studied to a higher detail. 
These clinical isolates were selected from different and diverging STs and further subjected to long-read 
NGS and phenotypic drug susceptibility testing (Table 3.2).  
 
Table 3.2 Kirby-bauer disk diffusion susceptibility tests for seven K. Pneumoniae clinical isolates from this study. The 
measurements of the zone sites are in millimetres. The quantity of antibiotic in each disk is indicated in brackets next to the 
name of each antibiotic (units: µg). AMC – 2:1. R: resistant. S: sensitive. I: intermediate level of resistance. 
Clinical 
Isolate 
Antibiotic 
FOX (30) CTX (30) CAZ (30) IPM (30) CIP (5) GME (30) AMC (30) 
KP1208 20(S) 26(S) 7(R) 25(S) 23(I) 17(S) 11(R) 
KP1264 20(S) 6(R) 6(R) 21(S) 6(R) 10(R) 18(R) 
KP1363 18(S) 23(S) 19(R) 22(S) 26(S) 16(I) 19(S) 
KP1675 19(S) 7(R) 6(R) 23(S) 13(R) 7(R) 10(R) 
KP2209 18(R) 6(R) 6(R) 22(S) 22(I) 17(S) 12(R) 
KP2958 11(R) 13(R) 8(R) 19(I) 6(R) 7(R) 6(R) 
KP3860 19(S) 6(R) 6(R) 24(S) 6(R) 6(R) 9(R) 
 
All isolates but Kp1363 are resistant to AMC, whereas the seven isolates show resistance to CAZ. 
Five isolates are resistant to CTX and further classified as MDR. None of these isolates show resistance 
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to carbapenems albeit Kp2958, which show decreased susceptibility to the carbapenem imipenem. 
Taken together, these resistance profiles illustrate the accumulation of distinct genetic markers 
underlying phenotypic resistance resulting in the emergence of MDR strains which are associated with 
higher rates of tretament failure and mortality40-42. 
Long-read sequence data was de novo assembled using two approaches: a long-read only 
approach and an hybrid approach combining both long and short-read data (Supplementary Table 5.5). 
The first method of assembly yielded a total of eight plasmids; Kp1675 was poorly assembled using this 
method, and so no plasmids were identified. As for the hibrid assembly, 18 circularized and two non-
circularized contigs with an identifiable replicon were detected. Both sets of plasmids are listed on 
Supplementary Tables 5.6 and 5.7. Despite being concordant in the replicons detected and respective 
contig sizes (Supplementary Figure 5.1), the hybrid approach was selected as it enabled the assembly of 
Kp1675 and smaller Col-like plasmids, and the correction of the higher error rates associated with 
PacBio reads134. However, plasmid 3860_Pac15 was used since we were unable to fully assemble and 
circularize the 3860HYB9 plasmid through the hybrid assembly method.  
Overall, the sequence of 20 plasmids was obtained (Table 3.3), seven of which are multireplicon. 
The most common replicon is IncF, represented by IncFIA(HI1), IncFIB(K), IncFIB(AP001918), 
IncFIB(pKPHS1), IncFII and IncFII(K). The latter is the most frequent one (n=5), followed by IncFIB(K) 
(n=4). Other replicon types identified are ColRNAI (n=6), ColpVC (n=3), IncR (n=2) and IncQ (n=1). 
Interestingly, Kp1675 harbours two IncFII plasmids (1675HYB6 and 1675HYB8), which is 
surprising in the light of the beliefs that bacteria cannot stably maintain plasmids from the same Inc 
group83. However, for 1675HYB8, the percentage of identity of the IncFII replicon is only 83.6%, below 
the minimum of 95%93. As such, this replicon might comprise a new IncFII type replicon that has not 
yet been described. Similarly, Kp2209 also bears two IncFII(K) plasmids (2209HYB4 and 2209HYB6), 
but the percentage of identity is not 100% in neither of these replicons (97.3% and 95.3%, respectively). 
In both cases, these divergent multireplicon plasmids might have acumulated mutations that led to 
diverging incompatibility specificity87, explaining why Kp1675 and Kp2209 are hosts to plasmids 
apparently belonging to the same Inc groups. Alternatively, one of the replicons could be inactive. 
Seven out of the 11 Inc type plasmids were visible upon agarose gel electrophoresis of plasmid 
DNA extraction, although for one isolate (Kp2209), harbouring two plasmids of similar size, it was 
impossible to resolve the respective bands (Figure 3.3). Plasmids larger than 136 Kbp were not visible 
on the gel. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Agarose gel electrophoresis gel of plasmid extraction from seven K. pneumoniae clinical isolates.  
1: Kp1208. 2: Kp1264. 3: Kp1363. 4: Kp1675. 5: Kp2209. 6: Kp2958. 7: Kp3860. 8: E. coli CF604. 9: E. coli CF804.  
A: 1264HYB7. B: 1363HYB4. C: 1675HYB6. D: 1675HYB8. E: 2209HYB5/2209HYB6. F: 2958HYB4. 
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1     2      3      4       5      6      7       8      9 
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Table 3.3. Size, replicons and antibiotic resistance genes present on the plasmids used in this study, belonging to seven K. pneumoniae clinical isolates. The antibiotic resistance portion of the table was built by combining the information obtained from the 
ResFinder and the NCBI Bacterial Antimicrobial Resistance Reference Gene databases. The numbers in red are bellow the PlasmidFinder cut-offs for the percentage of identity (95%). The numbers in brackets (“(2×)” or “(3×)”) indicate the number of copies of that 
gene on that plasmid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid 
Replicon(s) 
Size 
(bp) 
Antibiotic Class 
Replicon type 
% of 
Identity 
% of 
Coverage 
Aminoglycosides β-lactams TET Fluoroquinolones Phenicol RIF Sulphonamides TRIM Streptogramin 
1208HYB2 IncFIB(K) 100 100 214 263 \ blaSHV-1 tet(D) \ \ \ \ \ \ 
1208HYB3 ColRNAI 91.11 69.23 3 584 \ \ \ \ \ \ \ \ \ 
1264HYB7 
IncR 
 
Inc FIA(HI1) 
100 
 
98.45 
100 
 
99.74 
96 966 
aph(3'')-Ib, 
 aph(6)-Id,  
aac(6')Ib-cr (2×), 
aac(3)-IIa,  
aadA1 
blaSHV-11, blaTEM-1B 
blaOXA-1, blaOXA-9,  
blaLAP-1, blaCTX-M-15,  
tet(D) 
aac(6')Ib-cr, 
qnrS1 
catA2, 
catB3, 
catII 
arr-2 sul1, sul2 dfrA14 vgaC 
1264HYB11 ColRNAI 90.43 72.31 4 167 \ \ \ \ \ \ \ \ \ 
1363HYB4 
IncFII(K) 
IncR 
IncFIA(HI1) 
97.97 
99.20 
98.97 
100 
100 
99.74 
112 046 \ \ \ \ \ \ sul1 dfrA5 \ 
1675HYB6 
IncFIB(AP001918) 
IncQ1 
IncFII 
98.51 
100 
100 
88.42 
100 
100 
136 696 
aph(3'')-Ib, aph(6)-
Id, aph(3')-Ia 
blaTEM-1B \ \ \ \ sul2 dfrA5 \ 
1675HYB8 IncFII 83.63 98.26 102 633 \ \ \ \ \ \ \ \ \ 
1675HYB16 ColRNAI 89.38 86.92 6 222 aph(3'')-Ib, aph(6)-Id \ \ \ \ \ sul2 \ \ 
1675HYB18 ColpVC 98.45 100 2 058 \ \ \ \ \ \ \ \ \ 
2209HYB4 
IncFIB(K) 
FII(K) 
100 
97.30 
100 
100 
210 388 \ blaCTX-M-15 \ \ \ \ \ \ \ 
2209HYB5 IncFIB(pKPHS1) 98.39 100 124 381 \ \ \ \ \ \ \ \ \ 
2209HYB6 
IncFII(K) 
IncFIA(HI1) 
95.27 
97.16 
100 
100 
120 870 \ blaTEM-1C tet(A) \ \ \ \ \ \ 
2209HYB17 ColRNAI 91.21 70 3 580 \ \ \ \ \ \ \ \ \ 
2209HYB18 ColRNAI 86.17 73.31 2 942 \ \ \ \ \ \ \ \ \ 
2209HYB19 ColpVC 98.45 100 2 058 \ \ \ \ \ \ \ \ \ 
2958HYB2 IncFIB(K) 98.83 100 197 024 aph(3'')-Ib, aph(6)-Id blaSHV-1 tet(D) \ \ \ sul1 \ \ 
2958HYB4 
IncFII(K) 
IncFIA(HI1) 
88.35 
94.59 
69.59 
100 
111 887 \ \ \ \ \ \ \ dfrA14 vgaC 
2958HYB6 ColpVC 98.45 100 2 058 \ \ \ \ \ \ \ \ \ 
3860_Pac15 
IncFIB(K) 
 
IncFII(K) 
95.93 
 
95.95 
100 
 
100 
247 887 
aph(3'')-Ib,  
aph(6)-Id (3×),  
aac(3)-IIa (3×), 
aac(6')-Ib-cr (3×) 
blaOXA-1, blaTEM-1B,  
blaCTX-M-15 (3×) 
tet(A) 
aac(6')-Ib-cr, 
qnrB1 
catB3 \ sul2 dfrA14 \ 
3860HYB85 ColRNAI 90.11 70 5 669 \ blaTEM-1A \ \ \ \ \ \ \ 
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3.3. Gene Content and Structural Analysis of Plasmidic Scaffolds 
In this study sample, Inc type plasmids range in size between 97.0–247.9 Kbp, whereas Col-like 
plasmids display, as expected, a much lower and narrower size range (2.1–6.2 Kbp). All Inc and three 
Col-like plasmids were functionally annotated using RAST; the remaining seven Col-like plasmids were 
too short for RAST annotation. Table S8 summarizes the gene content of all annotated plasmids, and 
physical maps of the Inc megaplasmids are represented in Figure 3.4. The annotated plasmids have 
between 3 and 297 ORFs. ColRNAI plasmids seem to have a lower %GC then the Inc plasmids (52.93% 
vs 42,16% on average, respectively). All Inc plasmids but 1264HYB11 and 1364HYB4 harbour genes 
coding for membrane transport proteins, mainly ABC transporters and proteins involved in conjugative 
transfer (the latter also not present on 2958HYB4). 1675HYB6 and 2209HYB5 harbour a phage replicon 
origin and genes coding for phage tail proteins, respectively. Except for 3860_Pac15, none of the 
remaining plasmids harbour fimbriae coding genes. Additionally, 2209HYB5 harbours a RGD sequence, 
a cell attachment sire recognised by multiple integrins135. The remaining plasmids do not contribute for 
celular adhesion during infection. However, virulence through iron metabolism and siderophore 
production is granted by genes coded on five plasmids (1264HYB7, 1675HYB6, 2209HYB4, 
2958HYB2 and 3860_Pac15). Furthermore, resistance to mercuric mercury is granted by the mer operon 
on 1363HYB4 and 2209HYB4. However, since merB is not present, they are classified as narrow-
spectrum mercury operons (these only confer resistance to inorganic mercury salts)136. Mercury 
resistance genes are important for bacteria persistance in soil with high concentrations of this metal, and 
are often co-localized with antibiotic resistance genes on mobile elements such as plasmids137. 
Regarding drug resistance, 27 drug resistance genes belonging to nine antibiotic classes were 
identified. The majority of these plasmids carry genes coding for β-lactamases (SHV-1, OXA-1 and 9, 
TEM-1A, B and C, LAP-1 and CTX-M-15) and/or aminoglycoside-resistance genes (aph(3'')-Ib, 
aph(6)-Id, aac(6')Ib-cr, aac(3)-IIa, aac(3)-IIa and aadA1). Despite the fact that all strains are resistant 
to third-generation cephalosporins (CAZ/CTX), only three carry an ESBL, blaCTX-M-15, mobilized on 
plasmids (1264HYB7, 2209HYB4 and 3860_Pac15). Additionally, two ESBLs are coded on the 
chomosomes of these isolates – CTX-M-15 on Kp1264 and SHV-28 on Kp2958 and Kp3860 
(Supplementary Table 5.9). The NCBI Bacterial Antimicrobial Resistance Reference Gene Database 
allowed the identification of blaLAP-1 on the plasmid 1264HYB7. To our knowledge, this is the first report 
of a K. pneumoniae isolate carrying this narrow-spectrum β-lactamase, and the first report of LAP β-
lactamase in Portugal. No fluoroquinolone-coding genes were detected on Kp1675 and Kp2958 
plasmids; CIP resistance in these isolates is probably being mediated by chromosomal oqxAB genes 
coding for efflux pumps (Supplementary Table 5.9). Kp1264 exhibits a high level of resistance to RIF 
(MIC > 100 µl/ml) when comparing with the other isolates (MICs of 25 or 50 µl/ml). Bioinformatic 
analysis show this is mediated by arr-2, coding for an ADP-ribosyl transferase. 
By comparing the the overall plasmid structural variability across the same replicon types, we 
show that IncFIB(K) plasmids are the most conserved Inc-type plasmids across the seven isolates 
(Figure 3.5). This high degree of homology suggests that this replicon is a major driver for the horizontal 
mobilization of drug resistance genes in K. pneumoniae portuguese clinical isolates, even ones from 
different STs and hospitals. The antibiotic resistance genes on 3860_Pac15 are located on a region 
lacking high levels of homology with the other IncFIB(K) and IncFII(K) plasmids. This large insertion 
likely reflects a mutational event leading to the capture of antibiotic resistance genes mediated by 
transposable elements. The IncFIA(HI1), IncFII and IncR plasmids show a decreased homology and 
less conserved regions upon comparison with IncFIB(K) plasmids. Similarly, the ColRNAI plasmids 
herein studied show a high degree of heterogeneity. The scaffold of the ColpVC plasmids, on the other 
hand, seem to share 100% of nucleotide identity. 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Physical maps of the Inc megaplasmids from this study. 
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Figure 3.5: Scaffold comparison of plasmid-associated contigs. For each alignment, only the contigs with the same replicon 
type were chosen. The bigggest contig from each group was used as a reference in all of the alignments and is indicated in the 
center of each circle. The antibiotic resistance genes present on the plasmid in the center of each image are marked in red. 
IncFIB(K) 
IncFII 
IncFIA(HI1) 
ColRNAI 
ColpVC 
IncFII(K) 
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Figure 3.5: Scaffold comparison of plasmid-associated contigs. (continuation) 
 
3.4. Genetic Context of Antibiotic Resistance Genes 
To gain further insight on the horizontal dissemination of drug resistance genes, the genetic 
environment of the highly disseminated blaCTX-M-15 was characterized along with arr-2 and blaLAP-1, 
which are uncommon among K. pneumoniae isolates. 
 
3.4.1. blaCTX-M-15 is Located on a Truncated Tn3 Transposon 
Kp1264 and Kp2209 carry one copy of blaCTX-M-15, while Kp3860 carries three. Even though this 
gene is present on different IncF or IncF/IncR plasmids, its genetic context is similar is these three 
isolates. Here, blaCTX-M-15 is always located on a similar Tn3 transposon outlined in Figure 3.6, which 
3 
4
 
5
4
 
1 
2 
IncR 
Figure 3.6. Comparison of blaCTX-M-15 genetic context in three K. pneumoniae clinical isolates. 1: 1264HYB7 
[IncR/IncFIA(HI1)]. 2: 2209HYB4  [IncFII(K)/IncFIB(K)]. 3, 4 and 5: 3860_Pac15 [IncFII(K)/IncFIB(K)]. HP: 
hypothetical protein 
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shows the presence of trpB (coding for a tryptophan synthase β-chain) downstream blaCTX-M-15 and a 
Tn3 transposase downstream of both genes. A IS6 element is found in all isolates, either on 3’ the end 
or flanking both ends of the transposon; there is also a ISEcp1 element in Kp1264 and Kp3860. This 
genetic environment, in particular the herein described for Kp3860, is similar to the one described by 
Eckert and collegues, who found blaCTX-M-15 in a Tn3 transposon truncated by ISEcp1, and followed by 
a blaTEM-1139. In the isolates from this study, resistance genes besides blaTEM-1 were found upstream of 
this transposon: various aminoglycosides resistance genes and the β-lactamase blaOXA-1. Other 
IncFII(K)/IncFIB(K) plasmids carrying blaCTX-M-15 have also been found to share this insertion of a 
ISEcp1-blaCTX-M-15 transposon in the a middle of a Tn3 transposon138. Together, our results support the 
extensive dissemination of blaCTX-M-15 across K. pneumoniae isolates with multiple STs through the 
lateral tranfer mediated by a Tn3 transposon on plasmids from different Inc groups. 
 
3.4.2. First blaLAP-1 in a K. pneumoniae isolate 
LAP-1 was first identified in qnrS-positive Enterobacter cloacae isolates, these two genes being 
strongly associated in other Enterobacteriaceae (mostly E. coli)140,141. This association is seen in plasmid 
1264HYB7, where qnrS1 was identified upstream blaLAP-1, as shown in Figure 3.7. In the 1579 bp that 
separate these two genes, there is an IS element from the IS3 that seems to have been truncated.  
 
  
 
 
Figure 3.7. Genetic context of blaLAP-1 on the plasmid 1264HYB7. 
 
This genetic context has been described before but for LAP-2142. Interestingly, LAP-2 was also 
described in Italy in a K. pneumoniae clinical isolate from the same ST as Kp1264 (ST147), this gene 
also being carried by a conjugative plasmid together with qnrS1143. The selective force behind this 
specific genetic association remains unclear, but it is undoubtedly a gain to the bacteria when it is under 
the pressure of a combined antibiotic therapy of quinolones and narrow-spectrum β-lactams. 
 
3.4.3. arr-2 is Located on a Novel Class 1 Integron  
Herein, arr-2 was found to be located on a class I integron represented on Figure 3.8 and 
colocalized with other antibiotic resistance genes: aadA1 and cmlA5. This comprises a novel integron 
(In1264) associated with RIF resistance. The selective pressure driving the mobilization of arr-2 is 
unknown, as RIF is usually reserved for anti-tuberculosis therapy144. However, when in combination 
with colistin, this antibiotic was proven to be effective in the treatment of infections by carbapenemase-
producing K. pneumoniae145,146. 
 
 
Figure 3.8. Genetic context of arr-2 on In1264, a class I integron on the plasmid 1264HYB7. 
 
3.5. Phylogenetic Analysis of K. pneumoniae Megaplasmids 
To investigate the structural diversification and search for similar plasmidic scaffolds, we 
compared the plasmids herein characterized with a global datset of 1652 plasmids available at the pAtlas 
database. Briefly, six phylogenetic trees were constructed for the IncFIA-like, IncFIB-like and IncFII-
like plasmids using different plasmids as reference for alignment. The pAtlas plasmids with a stronger 
phylogenetic relatioship with our plasmids, marked in blue in Figure 3.9 and listed on Table 3.4, were 
isolated not only from other K. pneumoniae strains but also from the Enterobacteriaceae Klebsiella 
oxytoca, E. coli and Enterobacter spp., mostly from the USA but also from Europe (Spain and UK), 
Asia (China and Israel) and Australia. This points to the worldwide dissemination of these plasmids, in  
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IncFIA_1264HYB7 
IncFIA_2209HYB6 
IncFII_1675HYB6 
Figure 3.9: Phylogenetic analysis of IncFIA, IncFIB and IncFII plasmids. The phylogenetic trees were named by combining the replicon of the plasmids contained on that three with 
the name of the plasmid used as a reference for alignment. For example, “IncFIA_1264HYB7” only comprises IncFIA plasmids and 1264HYB7 was the plasmid used as a reference. 
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Figure 3.9: Phylogenetic analysis of IncFIA, IncFIB and IncFII plasmids. (continuation) 
IncFIB_1675HYB6 
IncFIB_3860_Pac15
<IncFIB_3860_Pac1
IncFII_3860_Pac15 
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particular those from the IncFIB family.  
Scaffold comparison analysis using these plasmids corroborate the previous results, as the 
plasmids harbouring IncFIB-type replicons are also highly conserved: 1675HYB6, 3860_Pac15, 
1208HYB2 and 2209HYB4 have a very high degree of homology with the IncFIB plasmids from pAtlas; 
the last two only differ in DNA insertions of approximately 6-7 Kbp. The opposite can be said for the 
IncFIB plasmid 2958HYB, since their scaffold differs substancially. As for the IncFIA plasmids, the 
pAtlas plasmids with this replicon share a high degree of homology with 2958HYB4 but not with 
1264HYB7. Finally, 3860_Pac15 is structurally more similar to IncFIB plasmids than IncFII plasmids, 
which suggests this plasmid results from the incorporation of a IncFII replicon on a IncFIB type plasmid. 
 
Table 3.4. pAtlas plasmids with a stronger phylogenetic relationship with the Inc plasmids from this study. The numbers 
on the first column indicate the plasmid from this study with a closer phylogenetic relationship with the plasmids listed here. 
1: 1208HYB2. 2: 1264HYB7. 3: 1675HYB6. 4 :2009HYB4. 5: 2958HYB2. 6: 2958HYB4. 7: 3860_Pac15. 
NA: not available. The Pasteur scheme for ST determination was used for all E. coli isolates except for the one harbouring 
pG749_1, where the Achtman MLST scheme was used instead. 
 Plasmid Accession Number 
(and Name) 
Isolate Strain ST 
Geographic 
Location 
1 
NZ_CP025145_1 (NR5632_p2) K. pneumoniae NR5632 307 USA, NYC 
NZ_CP025148_1 (KP1766_p2) K. pneumoniae KP1766 307 USA, NYC 
NZ_CP025142_1 (KP1768_P2) K. pneumoniae KP1768 307 USA, NYC 
2 
NZ_CP018737_1 
(pKp_Goe_641-1) 
K. pneumoniae Kp_Goe_121641 101 North Africa 
3 
NZ_CP012636_1 (pSF-088-1) E. coli SF-088 1 
USA,  
San Francisco 
NZ_CP014489_1 (pG749_1) E. coli G749 131 USA, Seattle 
NZ_CP023363_1 (134q) E. coli 144 8 UK, Scotland 
NZ_CP018994_1 
(pECAZ147_1) 
E. coli Ecol_AZ147 716 Israel 
4 NC_024992_1 (pKp848CTX) K. pneumoniae NA NA NA 
5 NZ_CP027425_1 8 (unnamed) K. oxytoca FDAARGOS_335 149 USA, DC 
6 
NZ_CP018815_1 (tig00000003) E. cloacae AR_0002 171 NA 
NZ_CP027616_1 (unnamed4) K. pneumoniae AR_0096 11 NA 
NZ_CP010363_1  
(p34978-139.941kb) 
E. hormaechei 34978 NA USA 
NZ_CP025039_1  
(pNU-CRE047_2) 
K. pneumoniae NU-CRE047 11 USA 
7 
NZ_CP023947_1 (unnamed2) K. pneumoniae FDAARGOS_446 340 Canada 
NZ_CP025457_1 (P69-1) K. pneumoniae KP69 11 China,Shangai 
7 
NZ_CP028817_1 (pKp589-231) K. pneumoniae Kp589 NA Spain,Barcelona 
NZ_CP024500_1 (unnamed1) K. pneumoniae KSB1_4E 323 Australia 
NZ_CP024516_1 (unnamed1) K. pneumoniae KSB1_10J 323 Australia 
NZ_CP024483_1 (unnamed1) K. pneumoniae INF322 29 Australia 
NZ_CP024508_1 (unnamed2) K. pneumoniae KSB2_1B 323 Australia 
 
3.6. Horizontal Transfer of K. pneumoniae Plasmids  
To investigate the ability of these plasmids to disseminate across multiple hosts and the potential 
lateral dissemination of drug resistance genes, we started by performing conjugation assays using 
Kp2209 and Kp3860 as donor strains. The most suitable concentrations for transconjugant selection was 
chosen based on MIC results. All recipient strains had a RIF MIC higher than 100 μg/mL. The recipient 
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strains A. baumannii 1.1 and E. coli 1.1 had a CTX MIC of 32 μg/mL, while P. aeruginosa 1.1 MIC 
was 16 μg/mL. Kp2209 and Kp3860 had RIF MIC of 25 μg/mL and for CTX their MIC was 64 μg/mL.  
Conjugation assays between Kp2209 and E. coli 1.1 yieled three transconjugants: EC2209_A, 
EC2209_B and EC2209_C. All transconjugants were negative for the urease test, as expected for E. coli, 
and exhibited resistance to CAZ, CTX and and to amoxicillin in the presence of clavulanatea. Their 
resistance pattern (Table 3.5) is consistent with the transfer of 2209HYB4, a IncFIB(K)/IncFII(K) 
plasmid carrying blaCTX-M-15. 
 
Table 3.5. Kirby-Bauer disk diffusion susceptibility tests of three transconjugants: EC2209_A, EC2209_B and 
EC2209_C. The measurements of the zone sites are in millimetres. The quantity of antibiotic in each disk is indicated in 
brackets next to the name of each antibiotic (units: µg). AMC: 2/1. R: resistant. S: sensitive.  I: Intermediate level of resistance. 
Strain 
Antibiotic 
FOX (30) CAZ (30) CTX (30) IPM (30) CIP (5) GME (30) AMC(30) 
E. coli 1.1 22(S) 21(S) 25(S) 25(S) 27(S) 20(S) 24.5(S) 
Kp2209 18(R) 6(R) 6(R) 22(S) 22(I) 17(S) 12(R) 
EC2209_A 28(S) 15.5(R) 9(R) 31(S) 31(S) 21(S) 15(R) 
EC2209_B 28(S) 16(R) 9(R) 31(S) 31(S) 22(S) 15(R) 
EC2209_C 26.5(S) 16(R) 9(R) 30(S) 31(S) 20(S) 12(R) 
 
Conjugation between Kp3860 and E. coli 1.1 yielded two transconjugants: 3860EC_A and 
3860EC_B. Both acquired resistance to CAZ, CTX, CIP, GME, TE, SXT and AMC (Table 3.6). This 
is consistent with the transfer of 3860_Pac15, an IncFIB(K)/IncFII(K) plasmid harbouring resistance 
genes for the following classes: β-lactams, aminoglycosides, fluoroquinolones TET, sulphonamides and 
TRIM. These transconjugants were also submitted to the urease test, which was negative for both. 
 
Table 3.6. Kirby-Bauer disk diffusion susceptibility tests of two transconjugants: 3860EC_A and 3860EC_B. The 
measurements of the zone sites are in millimetres. The quantity of antibiotic in each disk is indicated in brackets below the 
name of each antibiotic (units: µg). AMC: 2/1. SXT: 1.25/23.75. R: resistant. S: sensitive. No information is available for TET 
on EUCAST. NT: not tested. 
Strain 
Antibiotic 
FOX 
(30) 
CAZ 
(30) 
CTX 
(30) 
IPM 
(30) 
CIP 
(5) 
GME 
(30) 
AK 
(30) 
CHL 
(30) 
TET 
(30) 
SXT 
(25) 
AMC 
(30) 
E. coli 1.1 22(S) 21(S) 25(S) 25(S) 27(S) 20(S) 22(S) 20.5(S) 24 30.5(S) 24.5(S) 
Kp3860 19(S) 6(R) 6(R) 24(S) 6(R) 6(R) NT NT NT NT 9(R) 
3860EC_A 25(S) 13(R) 6(R) 30(S) 19.5(R) 6(R) 18(S) 28(S) 9 6(R) 15(R) 
3860EC_B 21.5(S) 6(R) 6(R) 30(S) 6(R) 10(R) 18(S) 21(S) 6 6(R) 6(R) 
 
Interestingly, 3860EC_A and 3860EC_B resistance levels to some antibiotics differ. 3860EC_A 
has a lower resistance level to CIP, CAZ and AMC, and a higher resistance level to GME, than 
3860EC_B when comparing the diameter of inhibition halos. This could be explained by an imbalance 
of the antibiotic influx/efflux mechanisms. To test this premise, the MICs of CIP, AMK, STR, GME 
and CAZ were determined and compared in the presence and absence of reserpine (Table 3.7). Reserpine 
is a plant alkaloid that is able to inhibit certain efflux pumps, being predominantly effective against 
fluoroquinolones147,148. The reduction of the MIC for CIP in EC3860_A from 1 µg/ml (resistant) to 0.5 
µg/ml (intermediate level of resistance) might indicate that the lower level of resistance for this 
transconjugant could be partially attributed to efflux pumps, as opposed to what happens with 
EC3860_B. There was also a decrease in STR and GME resistance in EC3860_A after adding reserpine, 
and in AMK resistance in EC3860_B.  
However, in these assays, reserpine led to a MIC decrease no greater than two-fold. A four-fold 
reduction or higher would be of greater significance148,149. These results indicate that other permeability 
mechanisms are likely involved in these resistance level differences, like mutations in certain porins. 
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An alternative explanation could be errors that might have led to the transfer of a truncated plasmid 
during conjugation, when the plasmid is cut, the open strand is unwound by a DNA helicase and the 
molecule is transferred to the recipient and the ends join to form to circularize the plasmid150. This 
hypothesis warrants further study by isolating and sequencing the plasmids from both transconjugants. 
 
Table 3.7. MIC assays for EC3860_A, EC3860_B, E. coli 1.1 and KP3860, with and without reserpine. Units: µg/mL. R: 
resistant. S: sensitive. I: Intermediate level of resistance. No information is available for STR and KAN on EUCAST. 
Antibiotic Conditions of Growth 
Isolate 
EC3860_A EC3860_B E. coli 1.1 KP3860 
AMK 
No Reserpine 16(I) 
= 
4(S) ↓ 
(2×) 
16(S) 
= 
8(S) 
= 
+ Reserpine 16(I) 2(S) 16(S) 8(S) 
GME 
No Reserpine >32(R) 
= 
8(R) 
= 
<0.5(S) 
= 
>32(R) 
= 
+ Reserpine >32(R) 8(R) <0.5(S) >32(R) 
KAN 
No Reserpine 256 ↓ 
(2×) 
32 
= 
8 
= 
128 
= 
+ Reserpine 128 16 8 128 
STR 
No Reserpine 256 ↓ 
(2×) 
8 
= 
8 
= 
256 
= 
+ Reserpine 128 8 8 256 
CAZ 
No Reserpine 64(R) 
= 
>64(R) 
= 
2(I) 
= 
>64(R) 
= 
+ Reserpine 64(R) >64(R) 2(I) >64(R) 
CIP 
No Reserpine 1(R) ↓ 
(2×) 
>16(R) 
= 
0.015(S) 
= 
>16(R) 
= 
+ Reserpine 0.5(I) >16(R) 0.015(S) >16(R) 
 
Both sets of transconjugants were positive for a conserved region of blaCTX-M-15 by PCR 
amplification, showing a band of approximately 600 bp (Figure 3.10). This result validates the transfer 
of plasmids carrying blaCTX-M-15 from Kp2209 and Kp3860 to E. coli.  
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Agarose gel electrophoresis of blaCTX-M-15 PCR products from the donor, recipient and transconjugants 
obtained in the conjugation assays between Kp2209 and E. coli 1.1. M: Molecular weight marker (NZYDNA LADDER 
VI). 1 and 2: EC2209_A. 3 and 4: EC2209_B. 5 and 6: EC2209_C. 7: E. coli 1.1. 8: Kp2209. 9: Negative control. 
 
No transconjugants were obtained from conjugation assays involving Kp2209/Kp3860 and P. 
aeruginosa or A. baumannii in three independent assays. These results corroborate the restricted 
dissemination of IncF plasmids among Entreobacteriaceae95. 
Additionally, to investigate if a transformation competent E. coli BL21DE3 cold be efficiently 
transformed by our K. pneumoniae plasmids, we attempted to transform this recombinant strain using 
plasmidic DNA from  Kp1264, Kp1675, Kp2209 and Kp2958, using both electroporation and heat shock 
methods. In all assays, pUC19 was used as control and efficiently transformed at high efficiency. None 
of the approaches were sucessful in obtaining transformants upon three independent attempts by 
electroporation. Contrarily, using the heat shock method, transformation with plasmidic DNA extracted 
from Kp1675 yielded transformants, and three of them were isolated: 1675A, 1675B and 1675C. STR 
and TRIM MICs are consistent with transformation with 1675HYB16, a ColRNAI plasmid harbouring 
aph(3'')-Id and aph(6)-Id but no TRIM-resistance genes (Table 3.8). 
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Table 3.8. MIC assays for STR and TRIM. R: resistant. S: sensitive. I: Intermediate level of resistance. 
Strain MIC for STR MIC for TRIM 
E. coli BL21DE3 16 µl/mL(S) 1 µl/mL(S) 
Kp1675 > 128 µl/mL(R) >16 µl/mL(R) 
1675A > 128 µl/mL(R) 1 µl/mL(S) 
1675B > 128 µl/mL(R) 1 µl/mL(S) 
1675C > 128 µl/mL(R) 1 µl/mL(S) 
 
At this point in time, transformation assays with Inc megaplasmids were unsuccessful, probably 
owing to their large size, leading to an inneficient transformation.  
 
3.7. Plasmid Stability Assays 
Finally, to investigate if the plasmids from this study can be efficiently maintained in its bacterial 
host in the absence of an antibiotic pressure, we performed plasmid stability assays on the isolates 
Kp1264, Kp2209, Kp2958 and Kp3860. Kp1264 was the only isolate where the loss of its megaplasmid 
from a bacterial population, a phenomenon called plasmid cure, was possible merely by removing the 
selective pressure of an antibiotic. The stochastic nature of plasmid loss in the host cell is evident in 
Figure 3.11, where its evident that this phenomenon happened at different rates on the three replicates. 
For the first and second replicas, after 10 cycles approximately 100% of the colonies lost resistance to 
RIF, which is consistent with the loss of the plasmid 1264HYB7; in the third replica, 10 cycles only led 
to around 14% of plasmid loss.  
 
 
 
 
 
 
 
Figure 3.11. Plasmid stability assay for Kp1264. 
 
At the end of the assay, three colonies were selected to study their resistance patterns; isolate A 
was resistant to RIF and isolates B and C lost resistance to this antibiotic (Table 3.9). The colocalization 
of aac(6')-Ib-cr and qnrB66 with arr-2 in the plasmid 1264HYB7 explains why the loss of resistance to 
RIP is of isolates B and C (MIC = 16 and 32 µl/mL, respectively) was accompanied by the loss of 
resistance to CIP (MIC = 2 µl/mL) when comparing the higher resistance levels of isolate A to these 
antibiotics (RIF MIC > 128 µl/mL; CIP MIC = 32 µl/mL). Isolates B and C remain resistant to CTX 
and GME due to the presence of a gene coding for the ESBL CTX-M-15 and genes enconding resistance 
to aminoglycosides on the chromosome (Supplementary Table 5.9). 
 
Table 3.9. Kirby-Bauer disk diffusion susceptibility tests for isolates A, B and C, obtained from plasmid stability assays. 
The measurements of the zone sites are in millimetres. The quantity of antibiotic in each disk is indicated in brakets next to the 
name of each antibiotic (units: µg). R: resistant. S: sensitive. 
Strain 
Antibiotic 
CAZ (30) CTX (30) CIP (5) GME (30) 
Isolate A 6(R) 6(R) 6(R) 6(R) 
Isolate B 9(R) 6R) 15(R) 6(R) 
Isolate C 9(R) 6(R) 15(R) 6(R) 
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3.8. Concluding Remarks and Future Perspectives 
K. pneumoniae continues to emerge as an important cause of hospital-acquired infections 
coupled with multidrug resistance. Therefore, it is becoming increasingly important to understand the 
molecular drivers of drug resistance and its dissemination mechanisms. This study comprises the largest 
ongoing sequencing effort of K. pneumoniae in Portugal to a very high standard, by contributing with 
novel data that partially fills an existing gap concerning plasmid diversity in K. pneumoniae isolated in 
Portugal. While most studies focus on carbapenemase-producing K. pneumoniae, showing higher 
prevalences of IncF (IncFIA, IncFIB, IncFII) as well as IncA/C, IncR and IncN plasmid types carrying 
ESBLs and carbapenemase genes151-154, we attempted to study a broader sample concerning drug 
resistance. The sequencing of these megaplasmids allowed us to better understand the dymanic of 
acquisition, loss and evolution of replicons. We showed that plasmid diversification at the level of the 
replicon leads to the emerence of novel replicon types and allows the co-existance of plasmids from the 
same Inc group on the same cellular line. Some limitations on this study are nevertheless present, since 
sequence data was limited to the Lisbon region, which could be imposing a geographical bias, as well 
as the fact that short-read sequence data is not able to detect multireplicon plasmids.  
The pylogenetic approach herein described allowed the identification of plasmids whose 
structure is similar to the ones from this study. IncFIB was found to be the most relevant replicon in the 
spread of antibiotic resistance, not only in Portugal but also globally, due to the strong conservation of 
the scaffold of the plasmids harbouring this replicon, as well as its widespread dissemination in different 
Enterobacteriaceae and its increase in prevalence throughout the years in Portugal. 
This study focused on plasmids as a highly important vehicle for the dissemination of drug 
resistance genes, which was found to be strongly linked with mobile elements such as integrons and 
transposons. Herein, blaLAP-1 was identified for the first time on a K. pneumoniae isolate, and the 
horizontal dissemination of ESBLs was corroborated, in particular CTX-M-15, which was found to be 
associated with a Tn3 transposon. Our results demonstrate the conjugative transfer of megaplasmids, 
which are able to efficiently disseminate across different species of Enterobacteriaceae despite of their 
large size, thereby acting as a genetic platfom combined with other mobile elements that can disseminate 
drug-resistance genes.  
Megaplasmids carrying genes coding for antibiotic resistance can persist in a population 
indefinitely, and very often removing the selection pressure of those antibiotics does not lead to plasmid 
cure, as it was demonstrated in this study. This can be explained by the fact that they harbour a diverse 
genetic content, so their contribution to the cell is not limited to antibiotic resistance. Although these 
plasmids harbour other genes encoding virulence factors that not only contribute to bacterial survival 
and establishment of infection in vivo but also to its environmental persistence, antimicrobial resistance 
comprises the problem with the highest clinical relevance.   
As the antimicrobial development pipeline is too slow when compared with the rate at which 
antibiotic resistance is rising globally, the research herein performed stresses that the fight against the 
antibiotic resistance crisis would be effectively complemented by preventing the mechanisms of 
horizontal gene transfer. To reach this goal, one of the main targets could be the machinary involved in 
plasmid secretion as e.g., blocking the activity of the protein relaxase (which cleaves the plasmids at the 
origin of transfer)155. In Portugal, this could even be targeted more specifically to IncFIB plasmids. 
Another possible approach is the study of compounds that promote plasmid cure in vivo. The concepts 
of plasmid incompatibility and interference have already been successfully used to cure a plasmid from 
different Enterobacteriaceae156. Both approaches constitute attractive avenues of research that, together 
with effective antibiotic stewardship, could potentially avert the mechanisms by which molecular 
determinants of resistance emerge, are selected and disseminate. The results conveyed in this work 
clearly show that  this difficult task can only be properly addressed by measures targeting these three 
stages of resistance development and dissemination. 
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5. SUPPLEMENTARY INFORMATION 
 
Supplemetary Table 5.1. Culture Media used in this study. Brands: (1) Biokar Diagnostic. (2) Oxoid ltd. (3) Liofilchem srl. 
(4) Fisher Bioreagents (5) Thermo Fisher Scientific.  
Culture Medium Brand or Composition (per litre of DDW) 
Cetrimide Agar  (1) 
Drigalski Agar (1) 
Müeller-Hinton Agar (MHA) (2) 
Müeller-Hinton Broth (MHB) (2) 
Luria-Bertani (LB) Agar  LB Broth + 15 to 16g of agar(2) 
Luria-Bertani (LB) Broth  10 g of peptone (3); 5 g of yeast extract(2); 5 g of NaCl(4);  
Super Optimal Broth (SOB) 
20 g of peptone(3), 5 g of yeast extract(2), 0.5 g of NaCl(4); mix 
the solutes and add 10 mL of a 250 mM KCl(4) solution; adjust to 
pH 7.0; before using, add 5mL of a 2M MgCl2(4) solution 
Super Optimal Broth with 
Catabolite Repression (SOC) 
SOB medium + a glucose(4) solution of 20 mM 
Stuart’s Urea Broth (5) 
 
Supplemetary Table 5.2. Composition of the solutions used for genomic DNA extraction. Brands: (1) Fisher Bioreagents 
(2) Fluka Analytical (3) Stratagene (5) Merck (6) Biochem Chemopharma. 
Solution Composition 
TE 10× 100 mM of Tris (1); 10 mM of EDTA(1) 
Lysozyme (2) 
Solution A 10 mg/ml Proteinase K(1); 10% SDS(4); proportion – 5:70 
CTAB/NaCl 4.1 g of NaCl (1); 10 g of CTAB (5) 
Solution B Chloroform (5); isoamyl alcohol (5); proportion – 24:1 
Isopropanol (6) 
Ethanol (6) 
 
Supplemetary Table 5.3. Composition of the solutions used for plasmid extraction. Brands: Solution I should be prepared 
on the day that it will be used and stored at 0°C. (1) Fluka Analytical (2) Fisher Bioreagents. (3) Merck KGaA. (4) Scharlau, 
S.L. 
Solution Composition 
Solution I 2 mg/ml of lysozyme(1); 50 mM of glucose(2); 10 mM of EDTA(2); 25 mM Tris(2) 
Solution II 0.2 M of NaOH(2); 1% of SDS(2) 
Solution III 3M of sodium acetate(3); adjust to pH 4.8 with acetic acid(4) 
 
Supplemetary Table 5.4. Antibiotics used in this study and their stock concentration.  
Antibiotic Stock Concentration Brand 
AMK 3.2 mg/mL in DDW Sigma Aldrich 
AMP 100 mg/mL in DDW Sigma Aldrich 
CAZ 20 mg/mL in DDW Acros Organics 
CIP 0.5 mg/mL in a 0.1 NaOH solution (Fisher Bioreagents) Fluka Analytical 
CTX 50 mg/mL in DDW Acros Organics 
GME 50 mg/mL in DDW Fluka Analytical 
KAN 8 mg/mL in DDW Sigma Aldrich 
RIF 50 mg/mL in DMSO Alpha Aesar 
STR 60 mg/mL in DDW Sigma Aldrich 
TET 20 mg/mL in DDW Sigma Aldrich 
TRIM 20 mg/mL in DDW Sigma Aldrich 
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Supplemetary Table 5.5. HGAP and hybrid assembly of seven K. pneumoniae clinical isolates. #: number. 
Clinical 
Isolate 
HGAP assembly Hybrid assembly 
# of 
contigs 
Biggest 
contig  
N50 
Genome 
size (bp) 
# of 
contigs 
Biggest 
contig  
N50 
Genome 
size (bp) 
Kp1208 20 3742895 3742895 6122713 3 5365731 5365731 5583578 
Kp1264 5 4139307 4139307 5548101 24 3524830 3524830 5422328 
Kp1363 6 5238931 5238931 5482499 15 3090327 3090327 5446020 
Kp1675 34 1330879 1028569 5522023 34 1330879 1028569 5522023 
Kp2209 8 166365 163952 964202 38 2037192 1757597 5828647 
Kp2958 13 5618120 5618120 6139011 7 5354662 5354662 5822517 
Kp3860 4 5415949 5415949 5667305 251 498628 270268 5601363 
 
Supplemetary Table 5.6. Size of plasmid assemblies and therein identified replicons by the HGAP assembly. The names 
of the plasmids consist on the name of the strain followed by the letters “Pac” and the number of the contig. Example: 
“1208_Pac15” is the contig number 15 of Kp1208. 
Plasmid Size (bp) Replicon(s) 
1208_Pac15 214 227 IncFIB(K) 
1264_Pac8 96 937 IncR / IncFIA(HI1) 
1363_Pac14 111 954 IncFII(K) / IncR / IncFIA(HI1) 
2209_Pac11 210 354 IncFIB(K) / IncFII(K) 
2209_Pac12 120 786 IncFIA(HI1) / IncFII(K) 
2209_Pac13 124 352 IncFIB(pKPHS1) 
2958_Pac21 196 977 IncFIB(K) 
3860_Pac15 270 100 IncFIB(K) / IncFII(K) 
 
Supplemetary Table 5.7. Size of plasmid assemblies and therein identified replicons by the hybrid assembly. The names 
of the plasmids consist on the name of the strain followed by the letters “HYB” and the number of the contig. Example: 
“1208HYB2” is the contig number 2 of Kp1208. *: this contig is not circularized. 
 
 
 
 
Plasmid Size (bp) Replicon(s) 
1208HYB2 214 263 IncFIB(K) 
1208HYB3 3 584 ColRNAI 
1264HYB7 96 966 IncR / IncFIA(HI1) 
1264HYB11 4 167 ColRNAI 
1363HYB4 112 046 IncFII(K) / IncR / IncFIA(HI1) 
1675HYB6 136 696 IncFIB(AP001918) / IncQ1 / IncFII 
1675HYB8 102 633 IncFII 
1675HYB16 6 222 ColRNAI 
1675HYB18 2 058 ColpVC 
2209HYB4 210 388 IncFIB(K) / IncFII(K) 
2209HYB5 124 381 IncFIB(pKPHS1) 
2209HYB6 120 870 IncFII(K) / IncFIA(HI1) 
2209HYB17 3 580 ColRNAI 
2209HYB18 2 942 ColRNAI 
2209HYB19 2 058 ColpVC 
2958HYB2 197 024 IncFIB(K) 
2958HYB4 111 887 IncFII(K) / IncFIA(HI1) 
2958HYB6 2 058 ColpVC 
3860HYB9* 247 887 IncFII(K) / IncFIB(K) 
3860HYB85* 5 669 ColRNAI 
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Supplemetary Figure 5.1. Scaffold comparison of the plasmids obtained by the hybrid assemblies and HGAP with the 
same replicons and similar sizes.  
1208HYB2 
1208_Pac15 
1264HYB7 
1264_Pac8 
1363HYB4 
1363_Pac14 
2209HYB4 
2209_Pac11 
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2209_Pac13 
2209HYB6 
2209_Pac12 
2958HYB2 
2958_Pac21 
3860HYB9 
3860_Pac15 
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Table 5.8. Gene content of 14 out of the 20 plasmids from study. The numbers indicate how many genes belonging to that class are harboured by each plasmid. 
 
Table 5.8. Gene content of 14 out of the 21 plasmids from study. (continuation) 
Plasmid Cell signaling Respiration Stress response Amino acids Mercury resistance Carbohydrates ORFs %GC 
1208HYB2 2 2 3 0 0 5 267 53.4 
1264HYB7 0 0 0 0 0 0 122 52.6 
1264HYB11 0 0 0 0 0 0 3 41.5 
1363HYB4 0 5 0 8 7 7 144 55.7 
1675HYB6 0 0 0 1 0 0 182 51.0 
1675HYB8 0 0 0 0 0 0 137 52.8 
1676HYB16 0 0 0 0 0 0 6 42.5 
2209HYB4 0 1 1 0 7 4 247 52.1 
2209HYB5 0 0 1 1 0 0 129 48.7 
2209HYB6 0 0 0 0 0 0 141 52.5 
2958HYB2 0 2 3 0 0 6 245 53.2 
2958HYB4 0 1 0 0 0 0 154 53.5 
3860_Pac15 0 1 1 1 0 8 295 52.5 
3860HYB85 0 0 0 0 0 0 7 42.5 
 
Plasmid 
Virulence, disease 
and defense 
Phages/Prophages, 
Transposable elements 
Membrane 
transport 
Iron acquisition 
and metabolism 
DNA 
metabolism 
RNA 
metabolism 
Nucleosides and 
nucleotides 
Protein 
metabolism 
1208HYB2 2 0 64 7 0 1 0 0 
1264HYB7 2 1 0 0 0 1 0 0 
1264HYB11 0 0 0 0 0 0 0 0 
1363HYB4 0 2 0 0 6 0 0 0 
1675HYB6 0 1 64 5 0 0 0 1 
1675HYB8 0 0 49 0 0 0 0 0 
1676HYB16 0 9 0 0 0 0 0 0 
2209HYB4 4 0 58 7 9 1 0 0 
2209HYB5 0 8 0 0 0 1 2 0 
2209HYB6 0 0 49 0 0 1 0 0 
2958HYB2 0 1 10 7 0 1 0 0 
2958HYB4 1 0 53 0 0 0 0 0 
3860_Pac15 0 1 56 7 0 1 0 0 
3860HYB85 0 0 0 0 0 0 0 0 4
2
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Supplementary Table 5.9. Antibiotic resistance genes present on the chromosome of seven K. pneumoniae isolates. 
Clinical 
isolate 
Size (bp) 
Antibiotic class 
Aminoglycoside β-lactam Fluoroquinolone Fosfomycin 
Kp1208 5 387 147 \ blaSHV-33 oqxa, oqxb fosa 
Kp1264 5 340 945 
aac(3)-IIa, 
aph(3")-b 
blaCTX-M-15, 
blaSHV-67 
oqxA, oqxB fosA 
Kp1363 5 349 971 \ blaSHV-59 oqxA, oqxB fosA 
Kp2209 5 391 817 aadA1 
blaSCO-1, 
blaSHV-75 
fosA sul1 
Kp2958 5 497 562 \ blaSHV-28 oqxA, oqxB fos(A) 
Kp3860 5 408 186 \ blaSHV-28 oqxA, oqxB fosA 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemetary Figure 5.2. Scaffold comparison of the pAtlas plasmids with a stronger phylogenetic relatioship with 
plasmids from this study. 
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Supplemetary Figure 5.2. Scaffold comparison of the pAtlas plasmids with a stronger phylogenetic relatioship with 
plasmids from this study. (continuation) 
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